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Antibioottiresistenssi on maailmanlaajuinen ongelma, joka uhkaa eri patogeenien aiheuttamien tautien hoitoa. 
Kaikki eliöt tuottavat ribosomaalisesti erilaisia pieniä peptidejä. Ne ovat laajalle levinneitä luonnossa ja niitä 
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paljon erilaisia bioaktiivisia peptidejä, joista monet ovat antimikrobisia ja mikrobigenomien arvellaan koodaavan 
monia tuntemattomia antimikrobisia peptidejä. Genomilouhinta on laajentanut ribosomaalisesti tuotettujen 
peptidien kirjoa viime vuosina. Bioinformatiiviset menetelmät yhdessä molekyylibiologian ja kemiallisen 
analyysin avulla pyrkivät tunnistamaan uusia bioaktiivisia peptidejä.  
 
Tietokannoissa julkaistuja bakteerigenomeita tutkittiin ja löydettiin uudenlainen geenijoukko, joka muistuttaa 
syanobaktiinien tuottogeenejä. Tuntematonta peptidiä koodaava geenijoukko löytyi syanobakteereista ja myös 
muista bakteereista. Työn tavoitteena oli tutkia geenijoukon esiintymistä eri bakteerien genomeissa ja niiden 
tuottamien peptidien mahdollisia rakenteita bioinformatiikan menetelmillä. Geenijoukon toiminta pyrittiin 
osoittamaan LCMS- ja Q-TOF -menetelmien avulla bioinformatiivisiin analyyseihin perustuen. Tavoitteena oli 
todistaa ennustettujen peptidien olemassaolo käyttämällä eri rikin isotooppeja kandidaattikannan kasvatusalustassa, 
jolla pyrittiin havaitsemaan kysteiiniä sisältävät peptidit. Lisäksi geenijoukon toiminta pyrittiin osoittamaan 
kloonaamalla peptidien tuottogeenit E. coli -bakteeriin ja tutkia peptidien antimikrobisia ominaisuuksia. 
 
Bioinformatiivisen analyysin mukaan tämä geenijoukko koodaa 1–8 esipeptidiä ja proteaasia. Esipeptidi koostuu 
konservoituneesta johtosekvenssistä (LPxQxxPVxR) sekä hyvin vaihtelevasta ydinpeptidistä, jossa on usein 
parillinen määrä kysteiiniä. Lopullinen peptidi muodostuu ydinpeptidistä esipeptidin translaation jälkeisten 
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Toisissa on 2–5 rikkisiltaa kysteiinien välillä ja osa vaikuttaisi muodostavan alfa-kierre-rakenteita. Tämän 
tyyppiset peptidit ovat yleisiä eukaryooteilla, mutta niitä on erittäin harvoin raportoitu bakteereista. Eukaryooteilla 
vastaavilla peptideillä on usein antimikrobisia ominaisuuksia ja ne ovat osana luontaista immuniteettia. 
 
Tässä työssä osoitettiin, että bioinformatiikan avulla ennustetut peptidit löytyivät syanobakteerikannasta 
Pseudanabaena sp. PCC 6802 käyttäen apuna molekyylibiologiaa sekä kemiallista analytiikkaa. Ilmentämällä 
geenijoukkoa heterologisesti todistettiin, että työssä tutkitut uudenlaiset geenijoukot tuottavat ennustettuja 
peptidejä. Lisäksi havaittiin, että lyhyet alfa-kierteiset kationiset peptidit, jotka ennustettiin Oscillatoria sp. PCC 
10802-, Dickeya zeae Ech1591-, Vibrio nigripulchritudo SOn1-, Agarivorans albus MKT 106-, Roseibium sp. 
TrichSKD4- ja Yersinia frederiksenii ATCC 33641 -kannoista, olivat antimikrobisia pitoisuuksissa 0.8–100 µg/ml. 
Tämän tutkimuksen tulokset todistavat, että bakteerit tuottavat kysteiiniä sisältäviä peptidejä ja jotkut peptidit tästä 
uudesta peptidiryhmästä ovat antimikrobisia, joita voidaan mahdollisesti hyödyntää lähtökohtana uutta lääkettä 
kehiteltäessä.  
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Antibiotic resistance is a worldwide problem and it threatens the prevention and treatment of infections caused by 
different pathogens. All living organisms produce natural products including ribosomal peptides with great variety. 
They are widely distributed in nature and they are playing more significant role in the search of new antimicrobial 
compounds used as therapeutical agents. Bacteria are a prolific source of peptides many of which are antimicrobial 
and microbial genomes are widely believed to encode new antimicrobial peptides. Genome mining has expanded 
the number of families of ribosomally synthesized natural products in recent years. These In silico approaches 
together with molecular biology and chemical analysis aim to identify novel compounds.  
 
In this study an unknown cyanobactin-like gene cluster was discovered by genome mining from genomes of 
cyanobacteria and also other bacteria. The aim of this work was to study the occurrence of the gene clusters in 
various bacterial genomes and the structures of novel peptides. The active biosynthesis of these peptides was tested 
by LCMS- and Q-TOF -analyses based on bioinformatic predictions. The production of the predicted peptides was 
also tested with stable sulphur isotope labelling. The aim was also to clone the genes needed for peptide 
biosynthesis into E. coli and to study antimicrobial activities of these peptides. 
 
Bioinformatic analyses suggested that the gene clusters encoded 1–8 precursor peptides together with protease. The 
precursor peptides had conserved leader sequence (LPxQxxPVxR) and a highly variable core sequences, often 
encoding an even number of cysteines. The mature peptide is eventually formed from core sequence through post-
translational changes in the precursor peptide. The gene cluster was present in 38 bacterial genomes representing a 
diverse selection of bacterial phyla including cyanobacteria, proteobacteria, actinobacteria, bacteroidetes, 
firmicutes and planctomycetes. Analyses of the precursor peptide core regions suggested that the products are 8–
131 amino acids in length. These peptides could be divided into two groups based on their structures: They form a 
selection of disulphide-bridge stabilized peptides with 2–5 disulphide-bridges as well as short cationic peptides 
with an α-helical structure. Surprisingly, these types of peptides are common in eukaryotes and part of the innate 
immune system displaying potent antimicrobial properties but very rarely reported for bacteria.  
 
The peptides predicted from bioinformatic analysis were detected from Pseudanabaena sp. PCC 6802 using a 
combination of molecular biology and structural chemistry. Heterologous expression of the gene cluster from 
Pseudanabaena sp. PCC 6802 in E. coli confirmed that the gene cluster is active. A set of short cationic synthetic 
peptides with α-helical structure predicted from Oscillatoria sp. PCC 10802, Dickeya zeae Ech1591, Vibrio 
nigripulchritudo SOn1, Agarivorans albus MKT 106, Roseibium sp. TrichSKD4 and Yersinia frederiksenii ATCC 
33641 were shown to have potent antimicrobial activity between 0.8–100 µg/ml. These findings prove that 
predicted cysteine containing peptides are produced by bacteria and some peptides from this novel family have 
antimicrobial activity, which might pave the way for new possible drugs derived from natural products.   
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1. LITERATURE REVIEW   
 
1.1 Natural products 
 
Natural products are produced by primary or secondary metabolism of living organisms 
(microorganisms, insects, plants and animals) (Demain and Sanchez 2009). The primary 
metabolites are common in all biological systems (Berdy 2005) and they are formed during the 
stationary phase of microorganism. The secondary metabolites are chemically and 
taxonomically highly various compounds (Berdy 2005) with different and usually important 
functions, but they are not vital for growth and reproduction. Secondary metabolites have had a 
considerable impact on the control of infectious diseases and the development of 
pharmaceutical industry, for example clinically important antibiotics of natural origin (Zerikly 
and Challis 2009). Additionally, many chemically synthesized drugs originate from natural 
products (Demain and Sanchez 2009). Microorganisms are an abundant source of more than 
20000 biologically active compounds (Demain and Sanchez 2009), many of these being 
peptides with exotic structures (Donia et al. 2008; Arnison et al. 2013).  
 
1.2 Genome mining for new natural products  
 
The proliferation of genome sequence data in public databases combined with research has 
enabled the discoveries of novel natural products from a broad diversity of micro-organisms 
(Challis 2008; Velázquez and van der Donk 2011; Bachmann et al. 2014). This huge quantity of 
accessible genome data works as a base for examination and discovery of new natural products 
(Zerikly and Challis 2009) with in silico approaches (Micallef et al. 2014). Genome mining 
includes examination of the sequenced genome of microorganism to conclude if gene clusters 
involved in the production of novel natural products can be found in these organisms (Scheffler 
et al. 2013). The classical approach for natural product discovery usually includes accurate 
screening of crude extracts from natural sources, such as bacteria, followed by chemical 
screening and bioactivity testing (Winter et al. 2011). This method is however often strenuous 
because of probable rediscovery of known natural products (Winter et al. 2011). Genome 
mining combined with modern techniques, such as LC-MS and Q-TOF, aims to product 
identification of novel gene clusters (Scheffler et al. 2013). 
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Genome mining is a powerful tool in the search for new secondary metabolites, because it links 
directly the discovery of new natural products with the genes encoding them (Zerikly and 
Challis 2009) and it has the theoretical potential to eliminate all chance from natural product 
discovery (Bachmann et al. 2014). Prediction of the amino acids included in ribosomal peptides 
is relatively straightforward by sequence comparison of similar systems and prediction of 
excision points of mature natural products encoded in larger precursor peptides (Challis 2008). 
Recognition of the protease cleavage sites in the precursor peptides enable detailed predictions 
of the mature peptide products (Velásquez and van der Donk 2011). Once the bioinformatics 
search is done, it is important for the user to manually check the output to inspect the 
authenticity of the identified gene clusters and to identify possible tailoring enzymes in the gene 
cluster. Eventually, novel gene clusters can be used for heterologous expression and bioactivity 
testing (Micallef et al. 2014).  
 
1.3 Non-ribosomal peptide synthesis (NRPS)  
 
Nonribosomal peptides and polyketides (PKS) have long been recognized as a source of a wide 
array of therapeutic agents (Hancock and Sahl 2006; Kopp and Marahiel 2007). These 
compounds are produced by large megaenzymes: Multimodular non-ribosomal peptide 
synthetases (NRPSs) and polyketide synthases (PKSs) (Finking and Marahiel 2004; Kopp and 
Marahiel 2007; Marahiel 2009). NRPSs assemble either proteinogenic or nonproteinogenic 
amino acids into the final peptide structure (Fischbach and Walsh 2006). PKSs assemble 
polyketides from acyl-CoA in a sequential aspect (Fischbach and Walsh 2006). The biggest 
portion of known complex secondary metabolites biosynthesis can happen by nonribosomal 
peptide synthetase (NRPS) or the mixed polyketide-NRP pathway (Tan 2007). In contrast to 
ribosomal machinery, non-ribosomal peptides are synthesized independently without mRNA 
(Finking and Marahiel 2004). While ribosomal peptide synthesis is usually limited to a set of 20 
amino acids as components of proteins, several hundred substrates of NRPSs are known 
(Marahiel et al. 1997). Some non-ribosomal peptides include unnatural amino acids and other 
molecules not found in ribosomal peptides (Finking and Marahiel 2004). Hence, structural 
variety is a predominant element of peptides produced by non-ribosomal machinery (Finking 
and Marahiel 2004).   
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Wang et al. (2014) studied 2699 genomes and cataloged 3339 NRPS,- and PKS gene clusters 
from the three domains of life. They suggest that these gene clusters show variable distribution 
in bacteria. They are widespread in the phyla Proteobacteria, Actinobacteria, Firmicutes and 
Cyanobacteria. They are also present in Ascomycota phylum in fungi (Wang et al. 2014). These 
peptides which are synthesized by fungi, bacteria and lower eukaryotes have been used as 
pharmacological agents including infection diseases, cancer and immunosuppression (Kopp and 
Marahiel 2007; Marahiel 2009). 
 
 1.4 Ribosomally synthesized and post-translationally modified peptides (RiPP). 
 
Ribosomal machinery is another strategy how bacteria synthesize modified peptides. 
Ribosomal peptides are natural products which are synthesized by translation of mRNA. 
According to Arnison et al. (2013) more structurally diverse peptides are emerging from the 
ribosomally synthesized and post-translationally modified peptide pathway (RiPP). This group 
is rapidly increasing and 20 families are known (Arnison et al. 2013). The precursor peptide 
consists of signal sequence, a leader peptide, a core peptide and a recognition sequence. The 
leader peptides are believed to have numerous roles in post-translational modifications and 
export (Arnison et al. 2013) and the core peptide encoded into the precursor peptide is 
eventually produced to form the mature RiPP through post-translational modifications (Figure 
1.3). Comprehensive post-translational modifications allow ribosomal peptides for better target 
recognition, to augment metabolic and chemical stability and to increase chemical 
functionality. RiPPs undergo a range of post-translational modifications which usually result in 
the restriction of the peptides conformational flexibility (Arnison et al. 2013). Common 
features for different classes of ribosomal peptides are for example macrocyclization and 
diminish conformational flexibility, and modifications to the N- and C-termini to restrain the 
sensitivity to degradation by exoproteases (Arnison et al. 2013). In all ribosomal peptides, the 
precursor peptide undergoes modification by tailoring enzymes which are usually found in a 
single genomic region (Dunbar and Mitchell 2013). Post-translational modifications include, 
among others, miscellaneous cyclizations, dehydrations, rearrangements, terminal capping, 
hydroxylations, oxidations, phosphorylations, glycosylations, reductions, targeting moieties 
and formation of disulphide bridges (Wang 2014). All these modifications endow the peptide 
with a rigidified structure and bioactivity (Dunbar and Mitchell 2013). Bacteria produce a wide 
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range of antimicrobial peptides through the posttranslational modification of short precursor 
proteins (Hassan et al. 2012; Arnison et al. 2013; Cotter et al. 2013). 
 
 
Figure 1.4. Biosynthesis for RiPPs from the precursor peptide (modified from Arnison et al 
2013). 
 
1.5 Antimicrobial peptides  
  
The antibiotic resistance is a global health problem and also lack of new antimicrobial 
medicines is another large concern (Tossi et al. 2000; Giuliani et al. 2007; Hassan et al. 2012). 
As a consequence, there is a compulsion for the development of new antimicrobial agents for 
clinical settings that are extensively effective and less likely to inflict antimicrobial resistance 
(Sang and Blecha 2008; Cotter et al. 2013). An antimicrobial peptide (AMP) is an agent that 
kills micro-organisms or hinders their growth. Antimicrobial peptides form four wide structural 
groups: 1) β-sheet peptides stabilized by two to four disulphide bonds (for example human α- 
and β-defensins); 2) α-helical peptides (for example magainin); 3) extended structures rich in 
glycine, tryptophan, proline, arginine and/or histidine and 4) cyclic peptides (Boman 1998; 
Hancock and Lehrer 1998; Hancock and Sahl 2006). From these, β-sheet peptides and α-helical 
peptides are most widespread in nature (Giuliani et al. 2007). 
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Natural gene-encoded antimicrobial peptides are produced in all forms of life, from micro-
organisms to multicellular organisms (Sang and Blecha 2008; Hassan et al. 2012) and they 
possess widely recognized activity against Gram-positive and Gram-negative bacteria and also 
fungi (Wimley and Hristova 2011). Most naturally appearing antimicrobial peptides are cationic 
and amphipathic (Jin et al. 2005). Cationic peptides are being examined as a new generation of 
antibiotics, in addition to innate immune modulators (Hancock and Sahl 2006). Most 
antimicrobial peptides are evolved from bigger precursors, including a signal (leader) sequence 
(Zasloff 2002), through one or more proteolytic activation steps (Hancock and Sahl 2006). 
Cationic antimicrobial peptides can be described as being short (10–50 amino acids), with a 
general positive charge (usually +2 to +9) and a significant portion (≥30%) of hydrophobic 
amino acid residues (Hancock and Lehrer 1998; Zasloff 2002; Giuliani et al 2007). These 
characteristics allow the peptide to fold into amphiphilic conformations in three dimensions, 
forming separate areas rich in positively charged and hydrophobic amino acids, often at the time 
of contact with membranes (Hancock and Sahl 2006; Giuliani et al. 2007).  
 
1.5.1 Mode of action 
 
AMPs bactericidal activity is expected to happen by interaction with cell membranes resulting 
in cell membrane integrity disruption. Cell death is being caused by efflux of metabolites and 
influx of ions (Nolan and Walsh 2009). Factors that affect AMPs molecular mechanism of 
membrane disruption are among others, amino acid sequence, peptide concentration and 
membrane lipids (Giuliani et al. 2007). AMPs can be divided into two mechanistic classes by 
their mode of action: Membrane disruptive (“barrel stave”, “micellar aggregate” and “carpet”) 
and non-membrane disruptive (intracellular targets) (Powers and Hancock 2003). In order to kill 
cells, AMPs must first have interaction with bacterial surfaces, and one mechanism is 
electrostatic bonding between cationic peptides and compounds on the bacterial cell wall 
(Brogden 2005). These compounds are lipopolysaccharide (LPS) in Gram-negative bacteria and 
polysaccharides, teichoic acids and lipoteichoic acids in Gram-positive bacteria (Brogden 2005). 
Once peptides have traversed outer membrane and achieved access to the cytoplasmic 
membrane they can interact with lipid bilayers (Brogden 2005). It is possible that cationic 
peptides are attached to anionic phospholipids that are plenteous in bacterial membranes 
(Powers and Hancock 2003). It is suggested that peptide interacts with target cells membrane, 
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this causes displacement of lipids and followed by change of membrane structure. Sometimes 
peptide enters the cytoplasm of target cell (Zasloff 2002).  
 
1.6 Antimicrobial peptides from eukaryotes 
 
1.6.1 α-helical peptides  
 
Linear α-helical peptides are one of the most plenteous and widespread in nature and seem to 
represent a successful structure in innate defense (Tossi et al. 2000), particularly in higher 
organisms including invertebrates, amphibians, fish and mammals (Tossi et al. 2000; Hassan et 
al. 2012). α-helical peptides adopt amphipathic structures only when in contact with 
membranes, meanwhile they are highly flexible in solution (Hancock and Sahl 2006). 
According to Tossi et al. (2000) they are most likely short (<40 amino acid residues), which 
makes them accessible to chemical synthesis. They are differently active against various 
pathogens, including Gram-positive and Gram-negative bacteria, protozoa, fungi (Tossi et al. 
2000), parasites, enveloped viruses and some cancer cells (Sang and Blecha 2008). 
Structure/activity relationship-studies have revealed at least seven factors that can impact the 
potency and activity of α-helical anti-microbial peptides: the size, the sequence, the helical 
content (%), the charge of the compound, the general hydrophobicity, the amphipathicity and 
the widths of the hydrophobic and hydrophilic sites of the helix respectively. All of these factors 
are closely related, so modifying one factor can result in remarkable changes to one or more of 
the other factors (Tossi et al. 2000). Antimicrobial capability is correlated with an amphipathic 
structure, an α-helix or a β-sheet. Moreover, β-sheet peptides occur to be more selective in 
contrast with amphipathic α-helical peptides. (Jin et al. 2005). 
 
1.6.1.1 Magainins  
 
Zasloff (1987) reported two 23 amino acid residues long peptides with broad spectrum 
antimicrobial activity from the skin of African clawed frog Xenopus laevis, called magainins. 
These peptides were shown to be active against Gram-negative and Gram-positive bacteria, 
fungi and protozoa (Zasloff 1987). A few years later Moore et al (1991) found out that 
magainins are also synthesized in the stomach of X. laevis and they undergo the same post-
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translational modifications as do those ones found in the skin (Moore et al 1991). Magainin 
peptides are amphiphilic α-helices by their structure (Zasloff 1987).  
 
Pexiganan, a synthetic analog of magainin, made it to Phase 3 clinical trials and was indicated 
for the treatment of diabetic foot ulcers. However, it was not approved by the US Food and 
Drug Administration (FDA) in 1999. This was a major setback for the whole industry of 
antimicrobial peptides as drugs. Pexiganan is, however, getting another chance entering clinical 
trials by another pharmaceutical company (Fox 2013). The major disadvantage of antimicrobial 
peptides in general is their high production cost compared to other types of antibiotics (Wimley 
and Hristova 2011). 
 
     1.6.2 Defensins 
 
Defensins are antibacterial peptides which are produced in mammals in the skin, lungs and gut. 
They are active against Gram-positive and Gram-negative bacteria and some defensins are even 
potent against viruses, fungi and protozoa (Nolan and Walsh 2009). Defensins form one of the 
largest group of antimicrobial peptides, the cationic peptides, which exist widely in animals and 
plants (Papagianni 2003). They have complex structural motifs and represent a large group of 4-
kDa open-ended, cysteine containing, amphiphilic peptides (Papagianni 2003). Defensins are 
divided into three groups: the α-defensins, the β-defensins and the insect defensins (White et al. 
1995). The α-defensins include 29–35 amino acids, the β-defensins 38–42 amino acids (White 
et al. 1995, Papagianni 2003) and the insect defensins 29–34 amino acid residues (White et al. 
1995). They are ribosomally produced and the active peptide is derived from bigger precursor 
(~60–100 amino acids) by post-translational proteolytic cleavage (Nolan and Walsh 2009). 
When aligned optimally, α-, and β-defensins share eight identical amino acid residues in their 
sequences, containing the six cysteines (Nissen-Meyer and Nes 1997; Papagianni 2003). About 
30 % of the amino acid residues are substantially conserved among the α-defensins, and 60-70 
% are well conserved among the β-defensins (Nissen-Meyer and Nes 1997). By their structure 
they are all cationic with arginine being the predominant cationic residue, and all defensins are 
stabilized by three disulfide bridges (White et al. 1995). Mammalian defensins (α-, and β) are 
rather different from plant defensins in their sequence and structure (Papagianni 2003) and they 
use an anti-parallel β-sheet, which is surrounded by cationic and hydrophobic residues (Zasloff 
2002). The predominant β-sheet with three stabilizing disulfide bridges is an integrating feature 
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that differentiates them from some other antimicrobial peptides, many of which are formed by 
amphiphilic α-helices (Nissen-Meyer and Nes 1997).  
 
1.6.3 Conus peptides and conotoxins  
 
According to Wang and Chi (2004) conus species have many venoms for feeding and defense as 
a survival strategy. Their venoms are mostly a mixture of bioactive peptides which are usually 
small and structurally constricted. These peptides have very high affinities and selectivities and 
they are optimized, among others, to target specific ion channels. Conus peptides are classified 
into two major classes: 1) majority with multiple disulphide bonds, indicated as conotoxins and 
2) minority with a single or no disulphide bond (Kaas et al. 2010; Wang and Chi 2004; Akondi 
et al. 2014), indicated as conopeptides (Terlau and Olivera 2004). It is estimated that there are 
5–10 conotoxin gene superfamilies that encode the majority of all conus peptides. Superfamilies 
of these peptides can be divided into various families based on functionality and structure, each 
with a specified pharmacological targeting precision (Olivera and Cruz 2001). Most of bioactive 
conus venom substances are small (sequence length 12–35 amino acids) structured peptides 
with exceptional potency and selectivity that target ion channels, and most likely these peptides 
have a specific ion channel as a suited target (Terlau and Olivera 2004; Kaas et al. 2010; Akondi 
et al. 2014). According to Kaas et al. (2010) conopeptides are ribosomal peptides which are 
synthesized by mRNA and translated into protein precursors. Precursors are later cleaved and 
they undergo various maturation steps to form the active peptide. They have a high prevalence 
of post-translational modifications which ends up in rich chemical diversities. Mature 
conopeptides are 8–86 amino acids in length, with an average of 26 amino acid residues (Kaas 
et al. 2010). 
 
Cone snail venom peptides, especially conotoxins, hold tremendous promise for the 
advancement of peptides as pharmacological drugs (Akondi et al. 2014). The small size, 
relatively easy synthesis route and target specificity of conotoxins and conopeptides makes them 
meaningful pharmacological probes (Lewis and Garcia 2003). It has been estimated that less 
than 0.1 % pharmacologically valuable conopeptides have been characterized out of 50000 
(Lewis and Garcia 2003). Conopeptides have eminent specificity for macromolecular targets 
which can be explained, among other reasons, by their high density of post-translational 
modifications (Kaas et al. 2010). The formation of disulphide bridges is the most common and 
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notably important because the protein 3D-structure can be rigidified and stabilized by cross-
linking the peptide between cysteine residues (Kaas et al. 2010). Other modifications include for 
example C-terminal amidation, proline hydroxylation, glutamate γ-carboxylation (Akondi et al. 
2014), sulphation (Tyr) and isomerization to D-amino acids (Lewis and Garcia 2003). Rigid 
secondary structure formed by disulphide bridges exhibits enhanced stability and potency in 
conotoxins in contrast to nondisulphide peptides (Akondi et al. 2014). Post-translational 
modifications are essential for bioactive venom-peptides in order to survive chemical and 
enzymatic degradation by processing proteases existing in the venom itself (Milne et al. 2003). 
 
1.6.4 Spider-venom peptides 
 
The chemical diversity of spider-venom peptides is astonishing: It is estimated that one venom 
can contain 200 bioactive peptides (King and Hardy 2013). Disulphide-rich peptides are widely 
represented in spider venom and they are to a great extent responsible of the venom’s 
insecticidal activity (Windley et al. 2012; King and Hardy 2013). Other peptides in the venom 
include linear and highly cationic cytolytic peptides (King and Hardy 2013) and they are active 
against Gram-negative and Gram-positive bacteria (Windley et al. 2012). It is however 
estimated that about 90 % of spider-venom toxins are globular disulphide-rich peptides, 
containing between one to seven disulphide bonds (Windley et al. 2012). Peptides in spider-
venom are typically larger in size compared to cone snail venom peptides (Milne et al. 2003). In 
addition to the disulphide-rich peptide neurotoxins (King and Hardy 2013), spider venom 
peptides have antimicrobial, antiparasitic and enzyme inhibitory activity (Saez et al. 2010). 
Most of these peptides affect by modulating the activity of ion channels and receptors (Saez et 
al. 2010).  
 
1.7 Cyanobacteria 
 
Cyanobacteria are one of the most successful and oldest life forms still present on earth which 
can be found aerial, terrestrial, marine, brackish, glaciers and fresh water environments. They 
symbolize an exceptionally versatile but extremely specialized group of microorganisms 
adjusted to various ecological habitats (Dixit et al. 2013). Cyanobacteria can be divided 
taxonomically into five different classes: Chroococcales, Pleurocapsales, Oscillatoriales, 
Nostocales and Stigonematales. According to Castenholz (2001) subsection I, Chroococcales, 
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undergo exclusively binary fission in comparison Pleurocapsales (subsection II) which 
reproduce through multiple fissions to produce smaller daughter cells, baeocytes. Organisms 
belonging to Oscillatoriales (subsection III) reproduce solely vertical to the growing axis. 
Strains in subsection Nostocales and Stigonematales (subsections IV and V, respectively) are 
able to comprehend specific cells. In other words, heterocysts (for nitrogen fixation) and can 
form akinetes (dormant cells) and hormogonia. Branching filament formation is also a 
connective feature for subsection V (Castenholz 2001). Toxin-producing cyanobacteria are 
often those which constitute mass occurrences in water (Sivonen and Börner 2008). These 
toxins can be harmful to humans and animals.  
 
      1.7.1 Secondary metabolites of cyanobacteria  
 
Cyanobacteria have been recognized as one of the most promising group of micro-organisms 
from which new and bioactive natural products are acquired (Burja et al. 2001; Singh et al. 
2005). These secondary metabolites can be biologically active peptides and/or toxins (Burja et 
al. 2001). Biggest portion of secondary metabolites from cyanobacteria are isolated from 
organisms belonging to Oscillatoriales (49%), then Nostocales (26%), Chroococcales (15%), 
Pleurocapsales (6%) and Stigonematales (4%) (Gerwick et al. 2008). Because of their high 
chemical stability and water solubility, these compounds have important applications (Dixit et 
al. 2013) (Table 1.6.1) alongside with their many biological activities such as anticancer, 
antimalarial, anti-HIV, antibiotic and toxic effect (Burja et al. 2001). One cyanobacterial 
genome can contain multiple biosynthesis pathways for natural products, making them similar 
to some actinomycetes and myxobacteria (Gerwick et al. 2008) which are example groups of 
organisms that are as chemically productive as cyanobacteria (Nunnery et al. 2010). 
Cyanobacteria stand for essential source of new microbial secondary metabolites, alongside 
with above-mentioned bacteria and fungi, in search for new drug discoveries (Tan 2007). 
However, genes responsible for secondary metabolite production are found in most 
cyanobacterial genomes regardless of what environment they are extracted from (Shih et al. 
2013).  
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Table 1.7.1. Examples of antimicrobial peptides from cyanobacteria 
 
Peptide(s) Producer strain Bioactivity Reference 
Hassallidins e.g. Anabaena sp. Antifungal Vestola et al. (2014) 
Brunsvicamides Tychonema sp. Antibacterial Müller et al. (2006) 
Spiroidesin Anabaena spiroides Anti-cyanobacterial Kaya et al. (2002) 
Lyngbyazothrins A-D Lyngbya sp. 
 
Antibacterial 
 
Zainuddin et al. (2009) 
 
Tolybyssidins A, B Tolypothrix 
byssoidea 
 
Antifungal 
 
Jaki et al. (2001) 
 
Lyngbyabellin B Lyngbya majuscula Antifungal Milligan et al. (2000) 
 
Balticidins A−D Anabaena cylindrica 
Bio33 
Antifungal Bui et al. (2014) 
Kawaguchipeptin B Microcystis 
aeruginosa 
Antibacterial 
 
Ishida et al. (1997) 
 
 
      1.8 Cyanobactins 
 
Cyanobactins are ribosomally produced, linear and N-to-C macrocyclic peptides with lengths 
ranging between 3–20 amino acids (Arnison et al. 2013; Leikoski et al. 2013), and they are 
widespread within cyanobacteria (Donia et al. 2008; Leikoski et al. 2013). Over 100 
cyanobactins have been isolated, making them one of the biggest and most important natural 
products in cyanobacteria (Schmidt and Donia 2009; Donia and Schmidt 2010). Various 
peptides belonging to this family are prenylated on Ser, Thr, or Tyr, while some are N-
methylated on His (Arnison et al. 2013). Cyanobactins contain oxazolines, thiazolines, or their 
oxidized derivatives oxazoles and thiazoles (Sivonen et al. 2010). Some of these peptides 
(anacyclamides) comprise only of proteinogenic amino acids (Leikoski et al. 2010).  
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Cyanobactins are produced through the posttranslational modification and cleavage of short 
precursor peptides (Sivonen et al. 2010). The precursor peptides include very conserved leader 
peptides and recognition sequences, but have very versatile core peptide sequences (Oman and 
van der Donk 2010). The high conservation of the leader and recognition sequences might 
indicate conserved recognition factors for the biosynthetic enzymes, while the multivariate core 
peptides makes high chemical diversity possible in the products (Oman and van der Donk 
2010). The leader sequence is flanked by recognition sequences which are expected to be the 
binding site for modifying enzymes responsible for post-translational modifications (Donia et al. 
2006; Houssen et al. 2010).  
 
1.8.1 Cyanobactin biosynthesis 
 
Cyanobactin gene clusters are about 10 kb in size and contain 7 to 12 genes (Sivonen et al. 
2010). The cyanobactin gene cluster encompasses two proteases which are responsible for 
cleavage of the precursor peptide and cyclization of the mature product, PatA and PatG (Lee et 
al 2009; Donia and Scmidt 2010; Sivonen et al. 2010). Eventually the 50–150 amino acids long 
precursor peptide is cleaved by proteases and modified to form the mature product (Donia and 
Schmidt 2010; Sivonen et al. 2010). PatA is responsible for proteolytic cleavage of the N-
terminal, when PatG catalyzes cleavage of the C-terminal recognition sequence at the same time 
with cyclization (Lee et al 2009). Macrocyclization happens via the peptide backbone and not 
along amino acid side chains (Agarwal et al. 2012) and most of these compounds are further 
processed by heterocyclization (Arnison et al. 2013). PatA and PatG are both subtilisin-like 
serine proteases (Oman and van der Donk 2010) and they both have a domain of unknown 
function (Agarwal et al. 2012). The gene order in the gene cluster is not severely conserved 
(Sivonen et al 2010).   
 
Some cyanobacteria have cyanobactin pathways, which produce highly modified short linear 
cyanobactins (Leikoski et al. 2013). Their length ranges from three to five amino acids with N-
prenylated and O-methylated termini in cyanobacterial strains Microcystis aeruginosa PCC 
9432 and Oscillatoria nigroviridis PCC 7112 (Leikoski et al. 2013).  
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     2. RESEARCH AIMS 
 
The objectives of this thesis project were 1) to map the distribution of cyanobactin-like gene 
clusters in different bacterial phyla; 2) Study and detect natural products from this novel 
pathway; 3) Production of detected peptides in heterologous host; 4) Bioactivity testing with 
synthetic analogs of peptides from this family (Figure 2). 
 
 
 
 
Figure 2. General workflow of natural product detection 
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     3. MATERIALS AND METHODS 
 
3.1 Bioinformatics 
 
Other than known cyanobactin gene clusters were searched using cyanobactin protease PatA by 
Blastp (Altschul et al. 1997). Blastp searches for cyanobactin protease PatA revealed a single 
S8-protease together with 1–8 precursor genes and these novel, divergent gene clusters from 
cyanobactin gene clusters, were mapped and examined further using NCBI and JGI databases. 
Core peptides encoded to larger precursor peptides from these clusters are hypothesized to be 
natural products of new ribosomal pathway. These products were named from now on 
cyanobactin-like peptides. 
 
Protease amino acid sequences of cyanobactin-like gene clusters from different bacterial strains 
were used to query the database at NCBI. The candidate cyanobactin-like gene clusters were 
collected and explored manually using Artemis (Rutherford et al. 2000). Artemis recognizes 
open reading frames from the selected genomic area. Open reading frames and annotated genes 
were manually examined for conserved amino acid sequences in the predicted leader sequence. 
Most of the predicted cyanobactin-like precursors were already annotated in the genome as 
hypothetical proteins, but open reading frames were additionally searched using conserved 
amino acid motifs present in the leader sequence (LPxQxxPVxR). Predicted precursor amino 
acid sequences were collected and aligned manually using the BioEdit sequence alignment 
editor. Hypothetical protease cleavage site was predicted in the precursor gene alignment. 
Proteases of the gene clusters were aligned using ClustalW for phylogenetic analysis.  
 
Phylogenetic analysis was done including MUSCLE alignment and excluding using GBLOCKS 
algorithm (http://www.phylogeny.fr/version2_cgi/simple_phylogeny.cgi).  
 
3.2 Synthetic peptides used for detection optimization  
 
Synthetic peptides were ordered from Genscript (USA, Inc.) according to predictions. Stocks of 
synthetic peptides were prepared in water, 100 % methanol, 50 % methanol and 0.1 % formic 
acid with concentration of 0.6 mg/ml of the peptide and used for dilution series (600 ng/ml, 60 
ng/ml, 6 ng/ml) in order to the detection limit of the peptides. Different peptide concentrations 
were analysed with cyanobacterial cell matrix (Cylindrospermum stagnale PCC 7417, 10.3 mg) 
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and without the cyanobacterial matrix to find out how the wanted peptide is detected from the 
bacterial backround. Both glass and plastic vials were used for LC-MS and Q-TOF to test how 
to prevent the attachment of the peptide to the vial.   
 
3.3 Strains and cultivation  
 
The bacterial strains included in the study were Leptolyngbya sp. PCC 7375, Gloeocapsa sp. 
PCC 7428, Calothrix sp. PCC 6303, Oscillatoria sp. PCC 10802, Microcystis aeruginosa PCC 
9443, Cylindrospermum stagnale PCC 7417, Pseudanabaena sp. PCC 6802, Mastigocladopsis 
repens PCC 10914, Tolypothrix PCC 7910, Streptomyces davawensis JCM 4913, 
Mesorhizobium alhagi HAMBI 3019 and Aurantimonas manganoxydans DSM 21871. S. 
davawensis JCM 4913 is a member of actinobacteria, M. alhagi HAMBI 3019 and A. 
manganoxydans DSM 21871 belong to the proteobacteria phyla. Cyanobacteria (PCC-strains) 
were grown in 40 ml of Z8-media (Kotai 1972) in constant light with a photon irradiance of 4–
10 µmol m-2 s-1 at 20–25 °C for 10−30 days. S. davawensis JCM 4913 was obtained from the 
Japan Collection of Micro-organisms and was grown in 50 ml of TY-broth (Tryptone 5,0 g/l, 
yeast extract 3,0 g/l, MgSO4 x 7H2O 2,0 g/l, distilled water 1,0 l) for 48 h. M. alhagi HAMBI 
3019 was obtained from HAMBI culture collection and was grown in 50 ml of modified TY-
broth (Tryptone 5,0 g/l, yeast extract 3,0 g/l, CaCl2 x 2H2O 0,7 g/l, distilled water 1 l) for 48 h. 
A. manganoxydans DSM 21871 was obtained from the German Collection of Micro-organisms 
and Cell Cultures and was grown in 50 ml of DSMZ-media 1326 (Peptone 2,0 g/l, yeast extract 
0,5 g/l, artificial seawater 980 ml (artificial seawater: NaCl 17,55 g/l, KCl 0,75 g/l, MgSO4 x 
7H2O 12,35 g/l, CaCl2 x 7H2O 1,46 g/l, distilled water 1 l)) for 48 h. 
 
Pseudanabaena sp. PCC 6802 was grown in Z8-media in larger scale for bigger biomass 
production for chemical analyses. Cultivation was carried out in 3 L culture bottles 35.1 L in 
total, with aeration, under light with a photon irradiance of 4–10 µmol m-2 s-1 at 20–25 °C for 14 
days. Cells were collected by centrifugation at 6000 × G for 10 min at 8–20 °C. The collected 
cells were freeze dried, which yielded to 6.17 g of dried cells.   
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3.3.1 Sulphur labeling  
 
Pseudanabaena sp. PCC 6802 was grown with 34S sulphur isotope instead of the normal 32S 
sulphur in Z8-media. Z8-media is made from three stocksolutions (Z8I, Z8II and Z8III) and 
from micronutrientsolution. The main sulphur source in Z8I-media is MgSO4 x 7 H2O. Z8I-
media was prepared without MgSO4 x 7 H2O and autoclaved. Autoclaved Z8I-media was added 
with sterile filtered (Whatman, Puradisc 25 mm, Sterile polyethersulfone membrane, pore size 
0.2 µm, Kent, UK) magnesium sulphate containing sulphur isotope 34S (MgSO4, ICON, Stable 
isotopes, IS7080, 90 atom % 34S) reaching stocksolution concentration of 0.1 mM, as it is 
described according to Kotai (1972). Both sulphur isotope labelled cell cultures were grown 
under light with a photon irradiance of 4–10 µmol m-2 s-1 at 20–25 °C for 14 days. 
Pseudanabaena sp. PCC 6802 34S-labeled cell extracts were compared with normal 32S 
containing cell extracts with LC-MS.    
 
3.3.2 Chemical analysis 
 
Cells were collected from the 40 ml-cultures by centrifugation at 7000 × G for 7 min 
(Eppendorf Centrifuge 5804 R, Eppendorf). All collected cells and their supernatants were 
freeze dried (Christ® Beta 2–8 LSCplus, LyoCube 4–8, Osterode am Harz, Germany) yielding 
10–55 mg. Freeze dried cells were extracted with 1 ml 50 % methanol and 200 µl of glass beads 
(Cell disruption media, 0.5 mm glass beads, Scientific industries, Inc.) by crushing 
mechanically with Fastprep cell disrupter (Bio 101, Thermo Electron Corporation, Qbiogene, 
Inc. Carlsbad, USA) at a speed of 6.5 m s-1 for 45 s. Suspensions were centrifuged at 20000 × G 
for 10 min and analyzed with LC-MS. Suspensions were filtered through 0.2 µm filter (13 mm 
syringe filter, PTFE, VWR international) for Q-TOF analysis.  
 
Cell extracts in 50 % methanol from candidate strains were analyzed with high resolution 
liquidchromatogram (HPLC, Agilent 1100, Agilent Technologies, Santa Clara, USA) combined 
with mass-spectrometer (MS, Agilent XCT Plus Ion Trap, Agilent Technologies, Santa Clara, 
USA). Compounds were separated in C8-column (Phenomenex® 100A Luna C8), which particle 
size was 5 µm, inner-diameter 2 mm and length 150 mm. Moving phase consisted of solutions 
A and B, which were 0.1 % watery solution of formic acid (A) and 0.1 % formic acid in 
isopropanol (B). At the beginning of analysis moving phase consisted of 5 % liquid A, but 
during analysis relation was altered evenly that after 35 min proportion of liquid B was 100 %. 
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Flow rate of moving phase was 0.15 ml min-1 and temperature was 40 °C. Fractured compounds 
were formed into positive ions, which were analyzed by MS in m/z-range 50–2200.  
Samples were also analyzed with high definition mass spectrometry (Q-TOF, Waters, 
SYNAPTG2-Si, USA). Moving phase consisted of solutions A and B, which were 0.1 % watery 
solution of formic acid (A) and 0.1 % formic acid in acetonitrile (B). At the beginning of 
analysis moving phase consisted of 95 % liquid A, but during analysis relation was altered 
evenly that after 5 min proportion of liquid B was 95 %, after 7 min proportion of liquid B was 
95 % and after 10 min proportion of liquid A was 95 %. Injection volume was 1 µl with high 
pressure limit of 15000 psi. Additional instrumental parameters were as follows: Polarity: ES+; 
capillary: 3.0 kV; source temperature: 120 °C; sampling cone: 40.0; source offset: 80.0; source 
gas flow: 0.0 ml/min; desolvation temperature 600 °C; cone gas flow 50.0 L/Hr. Fractured 
compounds were formed into positive ions, which were analyzed by MS in m/z-range 500–
2000. Calibration mass range was 622.7–1971.5.           
 
Identification of cyanobactin-like peptides was based on the theoretical molecular weights 
calculated from the predicted core peptide from candidate strains using ChemBioDraw. 
Theoretical molecular weights were compared with observed molecular weights resulted from 
Q-TOF and LC-MS. 
 
3.4 DNA extraction and determination of quality 
 
Genomic DNA was extracted from the strains Pseudanabaena sp. PCC 6802 and Streptomyces 
davawensis JCM 4913 using commercial DNA extraction kit (E.Z.N.A.® SP Plant DNA Mini 
Kit Protocol - Fresh/Frozen Samples, Omega Bio-Tek, Doraville, GA). Pseudanabaena sp. PCC 
6802 -cells were shaken with glass beads (acid washed, 425–600 µm or 710–1180 µm Sigma-
Aldrich, St. Louis, USA) 6.5 m s-1 30 s with shaker after addition of SP-buffer and RNAase-A. 
For other parts the work was carried out according to protocol for both bacteria. The DNA-yield 
was determined by NanoDrop (NanoDrop 1000 Spectrophotometer, Thermo Fisher Scientific, 
Wilmington, USA). 
 
3.4.1 PCR with 16S-primers 
 
The quality of DNA was controlled by 16S rDNA-PCR. This was done to make sure that 
possible false results in cyanobactin-like gene cluster amplification are not the outcome of bad 
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quality template DNA. PCR was carried out in 1 x DyNAzyme II enzyme buffer (Thermo 
Scientific), 200 µM of dNTP (Thermo Scientific), 0.75 µM of F-primer pA (Edwards et al. 
1989), 0.75 µM of R-primer B23S (Lepere et al. 2000), 0.4 U of DyNAzyme II DNA 
polymerase (Thermo Scientific) and 100 ng of template DNA in a final volume of 20 µl. PCR 
for Streptomyces davawensis JCM 4913 template DNA was carried out as described with one 
exception: Reverse primer was pH (Edwards et al 1989). The PCR was performed with an initial 
denaturation at 94 °C for 3 min; 30 cycles of denaturation at 94 °C for 30 s, annealing at 54 °C 
for 30 s, elongation 72 °C for 90 s and the final elongation step at 72 °C for 10 min.  
 
The size and the content of DNA was controlled by gel electrophoresis in room temperature 100 
V, 400 mA, 30 min, 0,9 % agarose in 0,5 × TAE-buffer (20 mM Tris, 10 mM acetic acid, 0.5 
mM EDTA, pH 8.3)  
 
3.4.2 Primer design for candidate strains and PCR 
 
Spesific primers were designed to amplify the gene cluster containing the genes for 
cyanobactin-like biosynthesis (Table 3.4.2). The primers were designed from the beginning of 
the protease gene to the end of the last precursor gene. For S. davawensis the primers were 
designed from the beginning of the protease to the end of the V8-like endopeptidase, including 
the precursors in between. PCR was carried out in 1 x Phusion green HF buffer (Thermo 
Scientific), 200 µM of dNTP (Thermo Scientific), 0.75 µM of each primer, 0.4 U of Phusion 
Green High-Fidelity DNA Polymerase (Thermo Scientific) and 100 ng of template DNA in a 
final volume of 20 µl. The PCR was performed with an initial denaturation at 94 °C for 3 min; 
30 cycles of denaturation at 94 °C for 30 s, annealing at 59.2 °C for 30 s, elongation 72 °C for 
90 s and the final elongation step at 72 °C for 10 min.  For S. davawensis JCM 4913 PCR was 
carried out as described above, but only specific primers JCM 4913_SpeIF and JCM 
4913_SallR were used (Table 3.4.2). PCR-program was also the same, but the annealing 
temperature of the primers was 63.9 °C. The size and the content of DNA was controlled by gel 
electrophoresis as described above. 
 
PCR-products were purified with commercial kit (Biotop, NucleoSpin® Gel and PCR Clean-up) 
and checked by NanoDrop (NanoDrop 1000 Spectrophotometer, Thermo Fisher Scientific, 
Wilmington, USA). 
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Table 3.4.2 Primer sequences for candidate strains for cyanobactin-like PCR amplification from 
Pseudanabaena sp. PCC 6802 and S. dawavensis JCM 4913. 
 
Primer Sequence 
PCC 6802_SpeIF 
 
5-AGGAACTAGTTGACTAGATGCAGTTACTTG-3 
 
PCC 6802_SalIRcR 
 
3-AAATGTCGACCCTTTATAGGCAATCAATG-5 
 
JCM 4913_SpeIF 
 
5-GGGACTAGTGGAACGGATGGACGTCCGG-3 
 
JCM 4913_SallR 
 
3-GCTCCGGCGGTCGACTGCCGTCGGTCAGT-5 
 
 
3.5 Plasmid constructs 
 
Insert (gene(s) of interest) and vector (plasmid) are first restricted enzymatically and ligated 
together forming recombinant plasmid (Figure 3.5) which is eventually transformed into E. 
coli.  
 
Figure 3.5. Procedure of using plasmid vectors to introduce foreign DNA in E. coli (modified 
from Goering et al. 2012). 
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3.5.1 Expression construct of Pseudanabaena sp. PCC 6802 
 
Plasmids and PCR-product from Pseudanabaena sp. PCC 6802 were restricted with two 
restriction enzymes; SpeI (Promega, Madison WI USA, 10 U/µl, lot 00000731139) and SalI 
(Promega, Madison WI USA, 10 U/µl, lot 0000111825). Restricted PCR-product was ligated 
into two different plasmids; low copy number Pacyc84 and high copy number Puc57 (see 
appendix). Ligations were carried out with insert-to-vector molar ratio of 3:1. 
 
Restriction digestion for insert (purified PCR-product, ~600 ng) was carried out with two 
restriction enzymes, SpeI and SalI as follows: DNA (purified PCR-product), water, SpeI (20 U), 
SalI (20 U) and 1 x Buffer (D, Promega, Madison WI USA, 10x, lot 29749708) ending with 
total volume of 40 µl. Vector (Pacyc184) was restricted similarly ending with total volume of 
40 µl. Both restriction mixes were incubated in +37 °C for 3 hours. Ligation mixture was 
prepared as follows: Insert-to-vector molar ratio of 3:1, water, 1 × Buffer T4 (Promega, 
Madison WI USA, 10x, lot 0000030467), 3 U of ligase T4 (Promega, Madison WI USA, 3 
U/µl, lot 0000081913) ending with total volume of 10 µl. Mixture was incubated overnight in 
room temperature. Puc57-vector was restricted as Pacyc184-vector ending with total volume of 
40 µl. Ligation mixture was prepared as follows: Insert-to-vector molar ratio of 3:1, 1 × Buffer 
T4, 3 U ligase T4. Mixture was incubated for 2 h in room temperature.  
  
3.5.2 Expression construct of S. dawavensis JCM 4913  
 
Method for constructing recombinant plasmid of S. dawavensis JCM 4913 PCR-product was as 
described for Pseudanabaena sp. PCC 6802 in paragraph 3.5.1. Restriction digest for insert was 
carried out as follows: DNA (purified PCR product, ~3000 ng), water, SpeI (20 U), SalI (20 U) 
and 1 × Buffer (D) ending with total volume of 40 µl. Both vectors (Pacyc84 and Puc57) were 
restricted similarly ending with total volume of 40 µl. Ligation was performed in 1 × ligation 
buffer, 3 U of ligase and 3:1 ratio of insert to vector for both plasmids. Ligation mixtures were 
incubated overnight in room temperature   
 
All restriction products were analysed on 0.9 % agarose gel (Bioline, Taunton MA, USA, lot 
ES520-BO17430) in 50 ml 0,5 × TAE- buffer (20 mM Tris, 10 mM acetic acid, 0.5 mM EDTA, 
pH 8.3) stained with Sybr Safe DNA gel stain (InVitrogen, lot 1531654, Carlsbad CA, USA). 
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Restriction mix (40 µl) was loaded in the well and in order to get the restriction products 
separated, DNA was controlled by gel electrophoresis in room temperature 100 V, 400 mA, 35 
min and was visualized using a dark reader (Clare Chemical Research Inc.).     
 
The gel was observed under UV-light and desired DNA-band was cut from the gel with sterile 
scalpel and placed to an Eppendorf-tube. DNA was purified from the gel with commercial kit 
(Qiagen, MinElute Gel Extraction kit) and yield was checked with NanoDrop. 
 
3.6 Heterologous expression in Escherichia coli 
 
Cloning and heterologous expression of the studied genes in E. coli was carried out in order to 
prove the existence of predicted cyanobactin-like peptides. In addition to Pseudanabaena sp. 
PCC 6802, S. davawensis JCM 4913 was chosen for the cloning. The plasmid constructs 
(described in 3.5.1 and 3.5.2) were transformed in chemically competent E. coli TOP10 -cells 
(Invitrogen, life technologies) according to manufacturer`s protocol.  
 
Blue-whitescreening with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) was used 
to detect the colonies containing the insert of interest. E. coli produces β-galactosidase, which 
fractures X-gal in the media, forming visually indicating blue colonies. Both of the used plasmid 
vectors, Puc57 and Pacyc84, contain lacZ-gene which produces β-galactosidase. These kind of 
cells fracture X-gal and form blue colonies. The multiple cloning site, where a desired insert 
was ligated into the vector, is located within the lacZ-gene. Successful ligation therefore 
modifies the open reading frame and disrupts the lacZ-gene. Then no functional β-galactosidase 
can form, resulting in white colonies. 
 
E. coli TOP 10 -cells grew on selective LB-plates (Tryptone 10 g/l, yeast extract 5 g/l, NaCl 5 
g/l, agar 15 g/l). Selectivity was determined by antibiotic selection: Chloramphenicol (1 ml/l) 
for Pacyc84 and ampicillin (2 ml/l) for Puc57. The result of cloning was checked by colony-
PCR with specific primers for both strains. PCR-program was as in chapter 3.4.2, but 
denaturation in the beginning at 94 °C was 10 min. Template was prepared mixing one colony 
with 10 µl liquid LB-media containing antibiotic from where 2 µl was used for PCR-reaction. 
Blue colony was picked as a negative control. PCR-products were checked with 
gelelectrophoresis as described in section 3.4.1. 
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3.6.1 Plasmid isolation from E.coli TOP10 -cells 
 
Colonies containing the ligated plasmid of interest, according to colony-PCR, were picked with 
sterile glass rod and inoculated in 5 ml LB with antibiotic in sterile glass tube. Glass tubes were 
grown in shaker +37 °C overnight. Plasmid was isolated with commercial kit (QiaPrep Spin 
Miniprep Kit, cat. nos 27104 and 27106) according to protocol from overnight cultures. Freezer 
stocks were prepared by adding 500 µl 85 % glycerol together with 500 µl cell culture and 
placed to -80 °C.  
 
3.6.2 Plasmid transformation into E.coli -BL21 cells  
 
Molecular cloning reaction and heterologous expression was done with Agilent Transformation 
Protocol (Catalog #200131 (BL21 (DE3) Competent Cells). Five colonies were picked with 
sterile glass rod and suspended to 5 ml of LB-media with selective antibiotic and grown 
overnight at +37 °C. The overnight cultures were used to inoculate fresh LB-media in sterile 
Erlenmeyer-flasks (2 × 50 ml) containing antibiotic to an OD600 0.05–0.1. The cultures were 
grown until they reached OD600 ~0.4. Other flask was induced with IPTG to a final 
concentration of 0.5 mM and other was kept as a control without IPTG induction. Cultures were 
incubated for an additional 2–3 hours, collected at 7000 × G for 7 min, freeze dried, extracted 
with 50 % methanol and analyzed with LC-MS as described earlier.  
 
 
3.7 Antimicrobial assays 
 
The peptides (11 pc., Table 3.7) were synthesized by GenScript according to predictions and 
tested against selected bacterial strains (Table 3.7.1). Some of these peptides are somewhat 
similar to known antimicrobial peptides by their sequence and structure so antibacterial activity 
was consequently supposed and this hypothesis was tested. The purity of synthetic peptides 
used in this study was between 75 %–98.8 % (Table 3.7). 
 
Stocks were prepared for antimicrobial peptides with concentration of 0.6 mg/ml in 50 % 
methanol. Bacterial strains were revived from -80 °C and grown on suitable media the time 
needed (Table 3.7.1). For antimicrobial testing a suspension of each bacteria was made reaching 
McFarland 0.5 in milli-Q water by picking 1–5 colonies. Sterile cotton bud was dipped into the 
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suspension and spread evenly on selective agar-plate. Each disk contained 60 µg of peptide. 
Peptide suspension was left to stand for 30-60 min so that the suspension would be adsorbed to 
the disk. Methanol (100 µl) was used as negative control and kanamycin (1000 µg/disk) as 
positive control. The plates were incubated 24 h or 48 h at temperatures 28 °C or 37 °C (Table 
3.7.1). After incubation the radius from the center of the disk was measured to the outer circle of 
the inhibition zone and reported in millimetres. Experiment was repeated twice. Second time 
peptides A and B were pipetted on same disk, 60 µg/peptide. This was done to see if there is an 
enhancement in antibacterial activity when peptides are used in tandem.  
 
Disk diffusion tests were also conducted with cysteine containing synthetic peptides (GASIS, 
NAVY, AAIF) which were used for detection optimization and they were 75 % pure (Table 
3.7). 
 
Table 3.7. Synthetic peptides included in disk diffusion experiment and MIC-test. 
 
Origin of peptide 
(purity of peptide) 
 
Tests 
done 
Length 
AA (core) 
 
Cysteine 
(core) 
 
Charge 
(core) 
 
Exact 
mass 
 
AA-sequence (core) 
 
Oscillatoria sp. PCC 
10802 A (75%)  
Disk 50 (25) 0 -1 2668.51 AWYDTVLDVVKTVAPIAAPILTSLI 
Oscillatoria sp. PCC 
10802 B (75%) 
Disk + 
MIC 
52 (24) 0 0 2558.44 AWYDTLLEVAKKVAPIATTVLGSL 
Dickeya zeae 
Ech1591 (98.8 %) 
Disk + 
MIC 
49 (22) 0 2 2272.29 FWGEALKLLKKAGQGALSGVLS 
Vibrio 
nigripulchritudo 
SOn1 A (98.1 %) 
Disk + 
MIC 
49 (22) 0 2 2325.75 FWGTAFDILKKAGKGALQGVMS 
Vibrio 
nigripulchritudo 
SOn1 B (98.1 %)  
Disk + 
MIC 
49 (22) 0 2 2294.22 FWGGVFDVLKKAGKGALQGVMS 
Oscillatoria sp.  
PCC 10802 C (75%) 
Disk 50 (25) 2 1 2684.24 GASISDYTSCYNLKGLARNLCMAAY 
Leptolyngbya sp. 
PCC 7375 C (75%)  
Disk 63 (31) 4 3 3670.76 IKRTHACRNAVYECQTIGHWPACDYVRKHCL 
Tolypothrix PCC 
7910 B (75%) 
Disk 54 (30) 2 -2 3140.55 AAIFGINLCDLMPEPERTACHIAGKLAGTE 
Agarivorans albus 
MKT 106  
(85.7 %) 
MIC 49 (22) 0 1 2229.60 FWGGVLDVLKKAGQGALNGVLS 
Roseibium sp. 
TrichSKD4 B  
(87.4%) 
MIC 53 (26) 0 3 2674.23 FWGALASAAAPIAIDLGKKALRGLLR 
Yersinia 
frederiksenii ATCC 
33641 (96.4%) 
MIC 49 (22) 0 1 2216.60 FWDSVLSVLKKAGQGALAGVLG 
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Table 3.7.1. Bacteria included in bioassay study. 
 
Bacteria (HAMBI nr.) 
 
Media 
 
Temp (°C) 
 
Incubation time (h) 
 
Pseudomonas sp. (2796) 
 
TGY 
 
28 24 
Pseudomonas aeruginosa (25) 
 
TGY 37 24 
Escherichia coli (396) 
 
TGY 37 24 
Burkholderia pseudanalbei (33) 
 
Nutrient 37 24 
Salmonella typhi (1306) 
 
Nutrient 37 24 
Xanthomonas campestris (104) 
 
Nutrient 28 24 
Burkholderia capacia (2487) 
 
TSA 37 24 
Bacillus cereus (1881) 
 
TSA 28 24 
Micrococcus luteus (2688) 
 
TGY 28 48 
Staphylococcus aureus (11) 
 
TSA 37 24 
Bacillus subtilis (251) 
 
TGY 28 24 
 
 
3.8 MIC (Minimum inhibitory concentration) 
 
MIC-value is the lowest concentration of an antimicrobial agent that inhibits the visible growth 
of a micro-organism. The bacteria studied included Staphylococcus aureus HAMBI 11, Bacillus 
subtilis HAMBI 251, Esherichia coli HAMBI 396 and Micrococcus luteus HAMBI 2688. The 
test was performed according to Wiegand et al (2008) protocol E with modifications. Bacterial 
cells were cultured in Müller-Hinton-agar at 37 °C. Synthetic peptides were dissolved in DMSO 
with concentration of 10 mg/ml (weighed 1 mg/100 µl).  This stock was used to make dilution 
series in ratio 1:2 (50 µl + 50 µl). Müller-Hinton-broth containing bacterial suspension and an 
antimicrobial peptide was prepared at various concentrations (100, 50, 25, 12.5, 6.25, 3.12, 1.56, 
0.78 µg/ml) in 96-well polypropylene-plate (150 µl/well: MH-broth 98.5 µl, bacterial 
suspension 50 µl and antimicrobial peptide 1.5 µl). Two parallel positive controls were used: + 
ctrl A (150 µl/well: MH-broth 98.5 µl, bacterial suspension 50 µl and DMSO 1,5 µl) and + ctrl 
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B (150 µl/well: MH-broth 100 µl and bacterial suspension 50 µl). Negative control was MH-
broth (150 µl/well). 
 
Bacteria were first grown overnight and cell counts were calculated (cfu/ml). From these 
cultures a bacterial suspension was made by picking colonies with a glass rod in 2 ml of 0.9 % 
NaCl reaching McFarland 0.5. This suspension was then diluted in relation 1:10 or 1:100, 
depending on the cell density, reaching roughly 105 cfu/ml. Prior to this dilution, the 
concentration of bacteria was adapted to give an initial optical density (OD) reading of about 
0.1–0.2 at 600 nm wavelength. Each bacteria was inoculated in its own 96-well plate to avoid 
contamination and incubated overnight at 37 °C. The MIC-value was taken as the concentration 
range of the antimicrobial peptide at which no bacterial growth was discovered with bare eye. In 
addition to sensory observation OD600-values were measured.  
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4. RESULTS 
 
      4.1 Discovery of novel peptidefamily – cyanobactin-like peptides 
 
An unusual cyanobactin-like gene cluster which encoded a single cyanobactin-like protease was 
found by mining draft and complete genomes, when cyanobactin proteases, PatA and PatG, 
were used to query the nonredundant database at NCBI. This resulted in a lot of hits many of 
which were cyanobactin gene clusters. Nonspesific hits to proteases were noticed which were 
not part of an actual cyanobactin gene cluster. The cyanobactin-like gene clusters were found in 
38 strains from different bacterial phyla including cyanobacteria, proteobacteria, firmicutes, 
actinobacteria, bacteroidetes and planctomycetes (Figure 4.1). These cyanobactin-like gene 
clusters differed from cyanobactin gene clusters by lacking the proteins for heterocyclization, 
macrocyclization and prenylation. The cyanobactin-like gene clusters encoded a single S8 
cyanobactin-like protease together with 1–8 precursor peptides with a varying length between 
8–131 amino acids which most could be identified through the presence of conserved motif 
(LPxQxxPVxR) in the leader sequence which they shared with known cyanobactin leader 
sequences. Furthermore recognizable cyanobactin precursor peptide cleavage sites (GxxxS) 
were present in many of the cyanobactin-like precursor peptides. The cyanobactin-like precursor 
peptides lacked the terminal recognition sequence of the cyanobactin precursor peptides. This 
suggested, together with the absence of the cyanobactin macrocyclase and other enzymes for the 
post-translational modification of cyanobactins, that the product of the gene cluster was a linear 
peptide. This information, together with the cleavage sites, made it possible to predict the 
product of the pathway with some degree of precision. The predicted post-translational 
modifications for the cyanobactin-like precursor peptides include proteolytic cleavage and 
formation of disulphide bridges which lead to mature natural product. The protease and the 
precursor(s) were the only enzymes common to all gene clusters and therefore it is likely that 
there are no further post-translational modifications beyond cleavage. The product of the gene 
cluster has highly conserved amino acid residues in their leader sequence which share homology 
between bacterial strains. The core sequences share no homology between bacterial strains and 
they are very variable (Table 4.1.2.2).  
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Figure 4.1. Widespread occurrence of cyanobactin-like gene clusters in 38 strains. 
 
 
The cyanobactin proteases and the cyanobactin-like protease had 40–50% identity. The protease 
was bimodular encoding two of the domains found in PatA and PatG proteins. Further 
inspection identified 2–8 short hypothetical open reading frames associated with the protease. In 
order to determine the distribution of this gene cluster across the bacterial domain BLASTp 
searches using the S8 protease as a query against the NCBI- and JGI databases were performed. 
Genome mining strategies illustrated that the biosynthetic genes for cyanobactin-like peptides 
are distributed widely between bacterial phyla. The size of the gene clusters was 2.3–5.0 kb in 
the candidate strains. Genomic organization and their putative genes encoding cyanobactin-like 
peptides of a selection of gene clusters are schematically shown in (Figure 4.1.1). Genome 
mining resulted to the discovery of cyanobactin-like gene clusters from 38 bacterial strains 
representing six bacterial phyla including 81 precursor genes. Proteases and some of the 
precursors are presented in more detail in Table 4.1.2. Precursor peptides are aligned in Figure 
4.1.2.1. Table 4.1.2.2 summarizes the predicted precursors from candidate strains and synthetic 
peptides used in this study. 
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In order to test these bioinformatics predictions we grew and extracted nine strains of 
cyanobacteria, two strains of proteobacteria and one strain of actinobacteria. Peptides 
corresponding to the bioinformatics predictions were detected from Pseudanabaena sp. PCC 
6802. The cyanobactin-like gene cluster in Pseudanabaena sp. PCC 6802 consists of subtilisin-
like protease, four precursor genes and one hypothetical protein. The size of the gene cluster is 
3485 bp. Three of the four core peptides derived from bigger precursor peptides were found and 
their m/z values matched well with bioinformatic predictions and theoretical masses, error rate 
being ≤3.5 ppm analyzed by Q-TOF. These detected peptides are linear by structure. These 
peptides were named cyanobactin-like peptides and they can be broadly divided into cysteine-
rich peptides and cysteine-poor peptides, with no disulphide bonds and they appear to be 
structurally different from each other.   
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Pseudanabaena sp. PCC 6802 (3500 bp) 
 
Leptolyngbya sp. PCC 7375 (5000 bp) 
 
Gloeocapsa sp. PCC 7428 (2300 bp) 
 
Aurantimonas manganoxydans DSM 21871 (2600 bp) 
 
Mesorhizobium alhagi HAMBI 3019 (2600 bp) 
 
Streptomyces davawensis JCM 4913 (3500 bp) 
 
Calothrix sp. PCC 6303 (2700 bp) 
 
Cylindrospermum stagnale PCC 7417 (2400 bp) 
 
Gloeocapsa sp. PCC 7428 (2300 bp) 
 
Tolypothrix sp. PCC 7910 (2700 bp) 
 
Microcystis aeruginosa PCC 9443 (2700 bp) 
 
Oscillatoria sp. PCC 10802 (4500 bp) 
 
Mastigocladopsis repens PCC 10914 (2750 bp) 
 
Figure 4.1.1. A selection of gene clusters found in the genomes of cyanobacteria, proteobacteria 
and actinobacteria. PseA illustrates protease and pseE precursor. Blue arrow indicates 
hypothetical protein. The abbreviation pse is derived from Pseudanabaena sp. PCC 6802.  
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Table 4.1.2. Proteases and precursors found by genome mining. 
 
  Protease 
 
    Precursor 
 
    
Bacteria Taxonomy Accession nr. Length AA Max identity 
(%) 
Organism Domains in 
protease 
Accession nr. Length AA Max identity 
(%) 
Organism Precursors 
Leptolyngbya sp. 
PCC 7375 A 
Cyanobacteria WP_006517599.1  676 63 Pleurocapsa sp. 
PCC 7319 
Peptidase S8, 
unknown 
WP_006517600.1  63 63 Leptolyngbya sp. 
PCC 7375  
8 
Gloeocapsa sp. PCC 
7428 
Cyanobacteria YP_007130541.1 632 74 Calothrix sp. PCC 
6303 
Peptidase S8, 
unknown  
YP_007130542.1 82 48 Cylindrospermum 
stagnale PCC 7417  
1 
Calothrix sp. PCC 
6303 
Cyanobacteria YP_007137041.1 636 74 Gloeocapsa sp. PCC 
7428 
Peptidase S8, 
unknown  
YP_007137042.1 128 59 Stanieria 
cyanosphaera PCC 
7437  
2 
Oscillatoria sp. PCC 
10802 
Cyanobacteria WP_017721275.1  669 58 Microcystis 
aeruginosa PCC 
9807 
Peptidase S8, 
unknown 
WP_008179623.1  82 44 Moorea producens 
3L  
5 
Microcystis 
aeruginosa PCC 
9443 
Cyanobacteria WP_002766681.1  371 (685) 71 Cylindrospermum 
stagnale PCC 7417  
Peptidase S8, 
unknown  
WP_002766678.1  poor hits   1 
Cylindrospermum 
stagnale PCC 7417 
Cyanobacteria YP_007146141.1 646 66  Calothrix sp. PCC 
6303 
Peptidase S8, 
unknown 
YP_007146140.1 81 48 Gloeocapsa sp. PCC 
7428 
1 
Pseudanabaena sp. 
PCC 6802 
Cyanobacteria WP_019502196.1  656 62 Calothrix sp. PCC 
6303 
Peptidase S8, 
unknown  
WP_019502198.1  125 38 Microcystis 
aeruginosa PCC 
9443 
4 
Mastigocladopsis 
repens PCC 10914 
Cyanobacteria WP_017317508.1  658 71 Acaryochloris 
marina MBIC 11017 
Peptidase S8, 
unknown  
No BLAST hits     2 
Streptomyces 
davawensis JCM 
4913 
Actinobacteria YP_007526447.1 824 51 Streptomyces sp. Peptidase S8, 
unknown  
YP_007526446.1 59 38 Sphingobium 
quisquiliarum P25 
5 
Mesorhizobium 
alhagi HAMBI 3019 
Proteobacteria WP_008834107.1  657 51 Mastigoclapsis 
repens 
Peptidase S8, 
unknown  
WP_008834108.1  58 32 Trichomonas 
vaginalis G3 
2 
Aurantimonas 
manganoxydans 
DSM 21871 
Proteobacteria WP_009208976.1  709 46 Hoeflea 
phototrophica DFL-
43 
Peptidase S8, 
unknown 
WP_009208977.1  130 38 Magnaporthe oryzae 
Y34 
1 
Yersinia 
enterocolitica subsp. 
Palearctica 105.5R 
Proteobacteria YP_004297516.1 575 99 Yersinia 
enterocolitica 
(Subtilisin DY) 
Peptidase S8, 
unknown 
YP_004297515.1 49 85 Agarivorans albus 
MKT 106 
1 
Agarivorans albus 
MKT 106 
Proteobacteria WP_016400604.1  648 57 Dickeya dadantii 
Ech586 
Peptidase S8, 
unknown 
WP_016400605.1  49 85 Yersinia 
enterocolitica subsp. 
Palearctica Y11 
1 
Roseibium sp. 
TrichSKD4 a 
Proteobacteria WP_009465765.1  687 40 Dickeya dadantii 
Ech586 
Peptidase S8, 
unknown 
WP_009465763.1  53 67 Roseibium sp. 
TrichSKD4  
2 
Clostridium sp. JC 
122 
Firmicutes WP_010299408.1  1045 44 Mastigoclapsis 
repens 
AAT_1 
superfamily, 
Peptidase S8, 
unknown 
(Glyco hydro) 
WP_010299410.1  79 34 Naegleria gruberi 2 
Shewanella 
piezotolerans WP3 
Proteobacteria YP_002314062.1 755 33 Candidatus 
Competibacter 
phosphatis  
Peptidase S8, 
unknown 
YP_002314064.1 52 81 Shewanella 
piezotolerans WP3 
2 
Moorea producens 
3L 
Cyanobacteria WP_008179627.1  1014 68 Oscillatoria sp. PCC 
10802 
Peptidase S8, 
unknown 
WP_008179625.1  51 54 Oscillatoria sp. PCC 
10802 
6 
Arthrospira 
platensis NIES 39 
Cyanobacteria YP_005071907.1 644 98 Arthrospira 
platensis C1 
Peptidase S8, 
unknown 
YP_005071906.1 71 99 Arthrospira sp. PCC 
8005 
3 
Mycobacterium 
vulneris  DSM 
45247 
Actinobacteria CDO33419.1 689 45  Arthrospira sp. PCC 
8005 
Peptidase S8, 
unknown  
CDO33418.1 61 44 Arthrobacter sp. 31y 3 
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Acaryochloris 
marina MBIC11017 
Cyanobacteria WP_012167256.1  653 71 Mastigoclapsis 
repens 
Peptidase S8, 
unknown  
No BLAST hits     1 
Planctomycete KSU-
1 
Planctomycetes WP_007222671.1  539 42 Streptomyces sp. 
Mg1 
Peptidase C1, 
unknown 
WP_007222670.1  131 33 Nitrosospira 
multiformis ATCC 
25196 
1 
Microcystis 
aeruginosa PCC 
9808 
Cyanobacteria WP_002792090.1  340 (667) 94 Microcystis 
aeruginosa NIES-44 
Peptidase S8, 
unknown  
WP_002766678.1  36 46 Moorea producens 1 
Planktothrix PCC 
8927 
Cyanobacteria AED99426.1 655 73 Anabaena sp. 90 Peptidase S8, 
unknown 
AED99427.1 129 69 Oscillatoria nigro-
viridis PCC 7112 
4 
Clostridium 
senegalense JC122 
(DSM 25507) 
Firmicutes WP_026022449.1  640 46 Oscillatoria sp. PCC 
10802 
Peptidase S8, 
unknown  
WP_010299410.1  56 41 Paenibacillus 
terrigena 
2 
Aurantimonas 
coralicida DSM 
14790 
Proteobacteria WP_029702737.1  695 47 Hoeflea 
phototrophica 
Peptidase S8, 
unknown  
WP_024348656.1  70 36 Azotobacter 
vinelandii 
1 
Candidatus 
Competibacter 
denitrificans 
Run_A_D11 
Proteobacteria CDI04438.1 638 55 Mastigoclapsis 
repens 
Peptidase S8, 
unknown  
No BLAST hits  65 38 Legionella 
longbeacheae 
1 
Candidatus 
Entotheonella sp. 
TSY2 
Proteobacteria ETX08109.1 340 67 Calothrix parietina Peptidase S8, 
thioredixin-like 
No BLAST hits     2 
Dickeya dadantii 
Ech586 
Proteobacteria WP_012886385.1  653 99 Dickeya zeae Peptidase S8, 
unknown  
WP_012886384.1  49 98 Dickeya solani 1 
Dickeya zeae 
Ech1591 
Proteobacteria WP_012768058.1  654 92 Dickeya zeae Peptidase S8, 
unknown  
WP_012768059.1  49 98 Dickeya dadantii 1 
Dickeya solani Proteobacteria WP_013319739.1  653 99 Dickeya dadantii Peptidase S8, 
unknown  
WP_022635150.1  49 98 Dickeya dadantii 1 
Vibrio 
nigripulchritudo 
SOn1 
Proteobacteria WP_022611399.1  657 55 Dickeya zeae Peptidase S8, 
unknown  
WP_022611398.1  49 69 Agarivorans albus 2 
Yersinia frederikseni 
ATCC 33641 
Proteobacteria WP_004708962.1  598 90 Yersinia 
enterocolitica 
Peptidase S8, 
unknown  
WP_004708955.1  49 85 Agarivorans albus 1 
Yersinia 
enterocolitica subsp. 
enterocolitica 8081 
Proteobacteria WP_011816805.1  559 89 Yersinia 
frederiksenii 
Peptidase S8, 
unknown  
No BLAST hits     
Janthinobacterium 
sp. RA13 (JGI) 
Proteobacteria 2585240732 637 50 Calothrix sp. PCC 
6303 
Peptidase S8, 
unknown  
2585240733 58 54 Aureispira sp. CCB-
QB1 
1 
Aureispira sp. CCB-
QB1 (JGI) 
Bacteroidetes 2587468798 645 41 Oscillatoria sp. PCC 
10802 
Peptidase S8, 
unknown  
2587468797 57 53 Janthinobacterium 
sp. RA13 
2 
Acaryochloris 
marina 
Cyanobacteria YP_001514993.1 590 97 Acaryochloris sp. Peptidase S8, 
unknown 
YP_001514994.1 65 34 Nematostella 
vectensis 
2 
Tolypothrix sp. PCC 
7910 
Cyanobacteria genome not public         2 
Streptomyces scabiei 
87.22 
Actinobacteria YP_003492207.1 290 85 Streptomyces 
bottropensis ATCC 
25435 
Peptidase S8, 
unknown 
YP_003492205.1 66 83 Streptomyces 
bottropensis ATCC 
25435 
3 
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Leptolyngbya sp. PCC 7375 A                        ~~~~~~~~~~~~~~~~MKSKRFSPILTIPVDRTKRDQQMNHNNSSV~~~~~~~~~~~SIQAS~~~~~~~~~~~~~~~LGWCRNDDDCGAGASCRYGTCVGDYL                                
Leptolyngbya sp. PCC 7375 B                        ~~~~~~~~~~~~~~~~MKRQSLLPITVPPVDRAGRDRQAS~~~~~~~~~~~~~~~~~GDISS~~~~~~~~~~~~~~~GSIAASGYFYDCDAHTDCPPGKICDGGICLNVPWY~                     
Leptolyngbya sp. PCC 7375 C                        ~~~~~~~~~~~~~~~~MKTKNLRPRLNAPVDRTNVVSIFKGQN~~~~~~~~~~~~~~GVSPS~~~~~~~~~~~~~~~IKRTHACRNAVYECQTIGHWPACDYVRKHCL                          
Leptolyngbya sp. PCC 7375 D                        ~~~~~~~~~~~~~~~~~~~~MRLPIQSLPVDRGISTTKVTQQN~~~~~~~~~~~~~~PINSS~~~~~~~~~~~~~~~ATYEQQQCTWAEYECHESDGTNATACNNYAAWGCTPNPRFSWNRVRVIRNF      
Leptolyngbya sp. PCC 7375 E                        ~~~~~~~~~~~~~~~~~~~~MKRPIQSPPVSRGASTAKAMLPG~~~~~~~~~~~~~~GVIAS~~~~~~~~~~~~~~~RLSRQCALWAEMCHIQDNQEACQLHQEQCQPRPNSPWGAHWQRRG            
Leptolyngbya sp. PCC 7375 F                        ~~~~~~~~~~~~~~~~MNHPTRMPRLSAPVDRAFTNQSVLS~~~~~~~~~~~~~~~~LRQES~~~~~~~~~~~~~~~IRAARQWCCTAEKNGQTINLGCNQPPWYHESGLFDSRDYDTVNCYPV          
Leptolyngbya sp. PCC 7375 G                        ~~~~~~~~~~~~~~~~~~~~MTLPRQVPPLKRPYFIQPHTVVDIVN~~~~~~~~~~~GTPDD~~~~~~~~~~~~~~~LFGIRMNLLHGANYNDPAPFDYRRVKQYSSMCCQRCALDATGIL             
Gloeocapsa sp. PCC 7428                            ~~~~~~~~~~~~~~~~~~~MMKLPVQAAPVQRGGSTARYTTSS~~~~~~~~~~~~~~GIKPS~~~~~~~~~~~~~~~ENLCSCHGVWFQCVINWNRCPQGYHPTCDGNGFNCFCRCCPDSGQGPCMGPYA    
Calothrix sp. 6303a                                ~~~~~~~~~~~~~~~~~~~~MKLPMQSQPILRKVSTAKIIST~~~~~~~~~~~~~~~DIVTS~~~~~~~~~~~~~~~GWNRPCNCTIPCRRSREACEDCFAACSPF                            
Calothrix sp. 6303b                                ~~~~~~~~~~~~~~~~~~~~MKLPIQAQPINRKVSSIPLDGSN~~~~~~~~~~~~~~GVKPQ~~~~~~~~~~~~~~~FFCPIGCGGGNFCPEGTFCTNTGFMSCECVPR                         
Oscillatoria sp. PCC 10802 C                       ~~~~~~~~~~~~~~~~~~~~MKLPNQSLPVSRRYLIQPD~~~~~~~~~~~~~~~~~~LVLVS~~~~~~~~~~~~~~~VKDSKGRLSRREYQYVHGSNPNPNAPMKFSEPADCGCPIFSGVSMAMCFAACGIF  
Oscillatoria sp. PCC 10802 D                       ~~~~~~~~~~~~~~~~~~~MNNLPKQSQPVVRNINTTSPLLNSS~~~~~~~~~~~~~GASIS~~~~~~~~~~~~~~~DYTSCYNLKGLARNLCMAAY~~~  
Oscillatoria sp. PCC 10802 E                       ~~~~~~~~~~~~~~~~~~~~MKLPIQAAAVSRHINTTLPQNTVGC~~~~~~~~~~~~GVKSS~~~~~~~~~~~~~~~GFCFYGAGDDPLAWTRAQAQYGYCPGTNAKVWVNNIGDGQNACTAGLFR 
Microcystis aeruginosa PCC 9443                    ~~~~~~~~~~~~~~~~~~~~MNLPIQIPPTSRKVSTAKLSGIR~~~~~~~~~~~~~~GFELS~~~~~~~~~~~~~~~NLALACDLCCQSGGGIACGAISGCSCPLWLFVTLYAKSTNKMPR            
Cylindrospermum stagnale PCC 7417                  ~~~~~~~~~~~~~~~~~~~~MKLPIQVVPVQRNLSIATYAMSS~~~~~~~~~~~~~~GIQAS~~~~~~~~~~~~~~~VFNPCACHAKGLGCIVTRNDCPAGWMPRCEVQLGAGCVCYCCSATGTCSGPY    
PCC 6802 A                                         ~~~~~~~~~~~~~~~~~~~~MLLPIQAPPKIRKVSPTKILGVMA~~~~~~~~~~~~~GINPS~~~~~~~~~~~~~~~NWKLRCDLCCEAGGGAVCNSILPGCVCPL                           
PCC 6802 B                                         ~~~~~~~~~~~~~~~~~~~~MKLPIQAQPVMRGVSSSKLAGK~~~~~~~~~~~~~~~TITPS~~~~~~~~~~~~~~~ECSYLRCGAKVLECASACYEGGVAACLACLGPSYEACKDCFSDIF           
PCC 6802 C                                         ~~~~~~~~~~~~~~~~~~~~MKLPIQAQPVLRQLNNYTSQHQ~~~~~~~~~~~~~~~GILPS~~~~~~~~~~~~~~~ASKCCGSDEYCLGSCICFLGDCSCAGACVPKL~~~                     
PCC 6802 D                                         ~~~~~~~~~~~~~~~~~~~~MKLPVQAQPVLRNVSDTKIAMTN~~~~~~~~~~~~~~AVIAS~~~~~~~~~~~~~~~GCSTWKKIGCAGAVAACAAVCYASGGLACAGCFAGLGQSSCIDCL           
Mastigocladopsis repens PCC 10914                  ~~~~~~~~~~~~~~~~~~~~MRIPNQSASQMRTISNMIWDDSI~~~~~~~~~~~~~~GINPL~~~~~~~~~~~~~~~QVLSTLLPIEGPNFDTCYRTCRFYGGGRVGCFLSCLSWIGTFAD            
Mastigocladopsis repens PCC 10914                  ~~~~~~~~~~~~~~~~~~~~MKLPNLSQSIQRSRLTSTVYQSS~~~~~~~~~~~~~~QMLPS~~~~~~~~~~~~~~~QLSITNEFEEENVRRTIVGYVRNIVSQGCFPCCFCCNQGNCCAECREKNLAANL  
Tolypothrix PCC 7910 A                             ~~~~~~~~~~~~~~~~~~~~MLLPIQTPPIIRKANTAKILDMM~~~~~~~~~~~~~~GVNPS~~~~~~~~~~~~~~~QNFQLQCALCCQNGGLATCNSILPGCVCRL                          
Tolypothrix PCC 7910 B                             ~~~~~~~~~~~~~~~~~~~~MKLPIQAQPIKRGVSTAHM~~~~~~~~~~~~~~~~~~QNLVN~~~~~~~~~~~~~~~AAIFGINLCDLMPEPERTACHIAGKLAGTE                           
S. davawensis JCM 4913 A                           ~~~~~~~~~~~MHETSPRPEPAVPVQAPAVRRDQWQAPADGATDR~~~~~~~~~~~~GAEAA~~~~~~~~~~~~~~~RSMCAGMTGSARDMCRSMGG     
Mesorhizobium alhagi HAMBI 3019                    ~~~~~~~~~~~~~~~~~~~~MKFPTQARPVARQTSKTRDETA~~~~~~~~~~~~~~~GIAPS~~~~~~~~~~~~~~~DCCGAGRCCVGACLPFGGGCAGICVPNIGQC                    
Mesorhizobium alhagi HAMBI 3019                    ~~~~~~~~~~~~~~~~~~~~MRLPNQARTVIRGRSADPFN~~~~~~~~~~~~~~~~~GAVGL~~~~~~~~~~~~~~~SGCNVFKAIRCAASVAACVASCAAGPAACIACFAGIGASDCMDCL      
Aurantimonas manganoxydans  DSM 21871              ~~~~~~~~~~~~~~~~~~~~MRLPMQASPVMRGQPLFMRSE~~~~~~~~~~~~~~~~GVRQS~~~~~~~~~~~~~~~GCNVLDWVVCGATVAACAPACVAGPATCALCMGAAYDRCKNCL        
Aurantimonas coralicida DSM-14790                  ~~~~~~~~~~~~~~~~~~~~MRSPMQSAPVMRGATFVTDSGGV~~~~~~~~~~~~~~GQSFS~~~~~~~~~~~~~~~WRCLLKCGVKLARCAPQCIPNPLSSGCISCLGSSYNTCKNCF         
Streptomyces scabiei 87.22 A                       ~~~~~~~~~~~~~~~~~~~~MTVPGFARDSASAGPGD~~~~~~~~~~~~~~~~~~~~LLHPQ~~~~~~~~~~~~~~~EITCERVEGPDCRSRCEGYDDADACYAACLADRCRDPAWWGGTP       
Streptomyces scabiei 87.22 B                       ~~~~~~~~~~~~~~~~~~~~MSLPGFTGSPARVTAGD~~~~~~~~~~~~~~~~~~~~RVVPQ~~~~~~~~~~~~~~~HITCEEEQGPPCSTQCAHSWNPAACRRECIEERCSGSWEWS          
Streptomyces scabiei 87.22 C                       ~~~~~~~~~~~~~~~~~~~~MRIPGFAVEPTAAHGANA~~~~~~~~~~~~~~~~~~~GDLLV~~~~~~~~~~~~~~~AQQFTCEEELRPVCRHQCRNSHHPAACVRQCLARLCDEGKW          
Candidatus competibacter denitrificans Run A D11   ~~~~~~~~~~~~~~~~~~~MRHLPKLSTGVIRDVQALKT~~~~~~~~~~~~~~~~~~GRSTA~~~~~~~~~~~~~~~QAAIYPSRWTCPNGGRPTATSEGCRCIDNTLGGLRDVGPCVWV        
Candidatus entotheonella A                         ~~~~~~~~~~~~~~~~~~~~MKLPIQSSGSRYTATKYAGVVKPRQQ~~~~~~~~~~~GIVPQ~~~~~~~~~~~~~~~RIKLQTWECSCDPDNPDICACESNGRIRVFHAVLGRL              
Candidatus entotheonella B                         ~~~~~~~~~~~~~~~~~~~~MRLPIQSAGVNRVGSGVSAVGTG~~~~~~~~~~~~~~GVIPQ~~~~~~~~~~~~~~~ILFDTRLTEAERCYYGYRSSGVPDLLARFFCGLRPFTIGGLLIPDRLGI  
Planktothrix PCC 8927 A                            ~~~~~~~~~~~~~~~~~~~MNYLPKQSQPIARSLNTTSPLLKSS~~~~~~~~~~~~~GVSSS~~~~~~~~~~~~~~~DFMDCYKLKGMARNICMAAY     
Planktothrix PCC 8927 D                            ~~~~~~~~~~~~~~~~~~~~MKLPNQSLPVNRREIIEPDLVVVSFKDSK~~~~~~~~GKWQQ~~~~~~~~~~~~~~~QYRYVRGSNSDPNESMKFSETLDCGCGIFSGLSRAMCFAACGVF                                 
Clostridium sp. jcc 122 A                          ~~~~~~~~~~~~~~~~~~~~MKLPLQAKPVSRNSFYTTPMDN~~~~~~~~~~~~~~~SVSPN~~~~~~~~~~~~~~~GFLCDMTCTLLPGDAQRICKEACAAGKTLCPTICSALPMPFNMMCSQACNLI                         
Clostridium sp. jcc 122 B                          ~~~~~~~~~~~~~~~~~~~~VKLPMQAKPVVRNLTQVSLKDK~~~~~~~~~~~~~~~GIKPN~~~~~~~~~~~~~~~QISTYEDCLINCNNLQSAIAREICKSLCR                                    
Shewanella piezotolerans A                         ~~~~~~~~~~~~~~~~~~~~MKLPTQSQPIERTTYTSHGA~~~~~~~~~~~~~~~~~GVGAE~~~~~~~~~~~~~~~ACSFWSSLASGALSAAKVVGPAILGAL                                                  
Moorea producens 3L B                              ~~~~~~~~~~~~~~~~~~~~MKLPKQSVPVKRPDLIDPSTTVDLQILIDA~~~~~~~GAVEE~~~~~~~~~~~~~~~LRNLKFDLLHGANYNNPMRFLMPANFCGCQIFSGQSRARCSATYGGL                              
Moorea producens 3L D                              ~~~~~~~~~~~~~~~~~~~~MKLPVQVKPVSRDSLGKTYLGFKT~~~~~~~~~~~~~GINPI~~~~~~~~~~~~~~~AALNQGRQVQASNGNLLAPPPPVNPGPTALPPISQNCKNCIDQQVGQGLSRSAAWNACFSIPTICPGA         
Moorea producens 3L F                              ~~~~~~~~~~~~~~~~~~~~MKLPNQASPVRRLVIQNYSGLQDTL~~~~~~~~~~~~EELAS~~~~~~~~~~~~~~~QRNSSELKLKKENDSSSPFKDAEETLEEVSSEGSSTKETPNPIPEPPDQIQEYPSDIGLWIKLCNFFSCIKNPPI  
Arthrospira platensis                              ~~~~~~~~~~~~~~~~~~~~MTFPKQSAPVKRPHFTQPALAVDLED~~~~~~~~~~~GEIED~~~~~~~~~~~~~~~LVHIRMDLLHGANYNDPAVFVPRSYNQVMHSGFASMGRFF                                     
Mycobacterium vulneris A                           ~~~~~~~~~~~~~~~~~~~~MNTPSRHTAAGALPPQRPGIARLDDDAR~~~~~~~~~GGFGT~~~~~~~~~~~~~~~GSVQASVSCGDLPGLARSMCYASKGIKY                                                 
Acaryochloris marina                               ~~~~~~~~~~~~~~~~~~~~MRIPNQSIGQIRSNPAIEKTAVSG~~~~~~~~~~~~~GVQPS~~~~~~~~~~~~~~~GPGLGRLCNEICRSPGGGGVCPLCEFLSLVPGF                                            
Planctomycete KSU-1                                ~~~~~~~~~~~~~~~~~~~~MKIPGFIAEASLYKTKGQYRTVA~~~~~~~~~~~~~~SYTIP~~~~~~~~~~~~~~~EIRVALQWCPDKRKCNSACYYCEAFGKQCGICDECKDCEPELPGDNGGESPPPKQYPTKPVCREEYERRCLPPPFNWFCWNECTRTCCYYQSPDQRFCGVEPC    
Microcystis aeruginosa PCC 9808                    ~~~~~~~~~~~~~~~~~~~~MNLPLQVPPTSRKVSTVRLSGIR~~~~~~~~~~~~~~GIELS~~~~~~~~~~~~~~~DLACDLCC                 
Janthinobacterium sp. RA13                         ~~~~~~~~~~~~~~~~~~~MNNLPLQAKAVQRSPSISAISQ~~~~~~~~~~~~~~~~GVAPS~~~~~~~~~~~~~~~GITCTLCKAACGALSGTAQQLCLMACNATVC                                                                 
Aureispira sp. CCB-QB1 A                           ~~~~~~~~~~~~~~~~~~~~MRIPMQSMPIGNQLNYNAKAT~~~~~~~~~~~~~~~~GVNES~~~~~~~~~~~~~~~GLPCTLCKLACNQLSGVAKTLCLLACDKTVC                                                                 
Aureispira sp. CCB-QB1 B                           ~~~~~~~~~~~~~~~~~~~~MKTPMQSMPIGIKTNYNSSSK~~~~~~~~~~~~~~~~GITTS~~~~~~~~~~~~~~~GIACTLCKTACQVLPIGARQLCELACDKTVC                                                                 
Moorea producens 3L E                              ~~~~~~~~~~~~~~~~~~~~MKLPNQASPVRRLVVQNYLGVQETL~~~~~~~~~~~~EEVAS~~~~~~~~~~~~~~~QRNSWELKLKKENDSSSPFEDIKKTFDIVAKSELEEVSSGESSTKETPNPIPEPPDQIQEYPSDTGLWTKLGRILQHLAMPAISRPSDSSGRVV  
Leptolyngbya sp. PCC 7375 H                        ~~~~~~~~~~~~~~~~MKRKKLRPKLSAPVDRTAIQASFKTDAIDNDK~~~~~~~~~GIYAS~~~~~~~~~~~~~~~KYHVKFASDDPTTYLLKMALLHLLVE                                                                      
Dickeya dadantii Ech586                            ~~~~~~~~~~~~~~~~~~~~MKLPTQAQNVNRANRVAEAKAS~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGEALNLLKKAGQGALSGVLS   
Dickeya zeae Ech1591                               ~~~~~~~~~~~~~~~~~~~~MKLPTQAQNVNRANRVAEAKAS~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGEALKLLKKAGQGALSGVLS   
Dickeya solani                                     ~~~~~~~~~~~~~~~~~~~~MKLPTQAQNVNRANRVAEAKAS~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGQALNLLKKAGQGALSGVLS   
S. davawensis B (hypo)                             ~~~~~~~~~~~~~~MNDTFAREERPTRPVALQTPFQTPAIDRTPTITR~~~~~~~~~GVDGS~~~~~~~~~~~~~~~DSNGVEADFDFGGLLKTVANVLL  
S. davawensis C (hypo)                             ~~~~~~~~~~~~~MTPTDKWREGRTSPTTALRTPYQTPAVDRTSAGSLGRGSDAD~~GVEPD~~~~~~~~~~~~~~~LGWSDIPWHAIGKAARGALDAVL  
S. davawensis D (hypo)                             ~~~~~~~~~~~~~MNDEFTPRRPGHGPVVPLRTPYQAPAIDRNTADLHGQRD~~~~~GADGV~~~~~~~~~~~~~~~EPNLPILPLLGLAGSAIGSLFD~  
Vibrio nigripulchritudo A                          ~~~~~~~~~~~~~~~~~~~~MKLPTQAPGVDRSNRLEAAQAA~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGTAFDILKKAGKGALQGVMS   
Vibrio nigripulchritudo B                          ~~~~~~~~~~~~~~~~~~~~MKLPTQAPGVDRSNRLEAAQAA~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGGVFDVLKKAGKGALQGVMS   
Yersinia frederiksenii ATCC 33641                  ~~~~~~~~~~~~~~~~~~~~MKLPIQAQSVNRSNRIAEAKMA~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWDSVLSVLKKAGQGALAGVLG   
Yersinia enterocolitica subsp. palearctica 105.5R  ~~~~~~~~~~~~~~~~~~~~MKLPIQAQSVNRSNRIAEAKMA~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWDSVLSVLKKAGQGALAGVLG~   
Agarivorans albus MKT 106                          ~~~~~~~~~~~~~~~~~~~~MKMPIQAQSVDRSNRIAEAKAA~~~~~~~~~~~~~~~GVNPA~~~~~~~~~~~~~~~FWGGVLDVLKKAGQGALNGVLS~  
Roseibium sp. TrichSKD4 a                          ~~~~~~~~~~~~~~~~~~~~MKLPYQAPSIDRANRLNSAIQQ~~~~~~~~~~~~~~~GVDPA~~~~~~~~~~~~~~LFGLDWDDVTGGLRSAVRYLAPHAKDAAKDFAMSAIDGL  
Roseibium sp. TrichSKD4 b                          ~~~~~~~~~~~~~~~~~~~~MKLPYQAPSINREDRINSAIDS~~~~~~~~~~~~~~~SVAPA~~~~~~~FWGALASAAAPIAIDLGKKALRGLLR~~~~~~~               
Oscillatoria sp. PCC10802 A                        ~~~~~~~~~~~~~~~~~~~~MNLPKQSAPVERTLAPTAISGQT~~~~~~~~~~~~~~GVEAS~~~~~~~~~~~~~~AWYDTVLDVVKTVAPIAAPILTSLI~               
Oscillatoria sp. PCC10802 B                        ~~~~~~~~~~~~~~~~~~~~MNLPKQVAPVERTLTPAAISGQS~~~~~~~~~~~~~~GVEAS~~~~~~~~~~~~~~AWYDTLLEVAKKVAPIATTVLGSL~                
Planktothrix PCC 8927 B                            ~~~~~~~~~~~~~~~~~~~~MNLPKQSAPVERTLAPSAMSGQS~~~~~~~~~~~~~~GVEAS~~~~~~~~~~~~~~AWYDTLLDVVKTAAPIAAPILTSLI~                
Planktothric PCC 8927 C                            ~~~~~~~~~~~~~~~~~~~~MKLPKQVAPVERTLTPSAISGQS~~~~~~~~~~~~~~GVEAS~~~~~~~~~~~~~~AWYDTLLDIAKKAVPIVSNVLGSL~                
Shewanella piezotolerans B                         ~~~~~~~~~~~~~~~~~~~~MKLPTQSQPIERTTYQSSAA~~~~~~~~~~~~~~~~~GMGAN~~~~~~~~~~~~~~~ASLALTPMLAQTLYPYMNL                     
Moorea producens 3L A                              ~~~~~~~~~~~~~~~~~~~~MKCPKQAVPVQRPSTSAAISNEK~~~~~~~~~~~~~~GVKPS~~~~~~~~~~~~~~~TTAFEEILRGTSGASGLEVTLKF                 
Moorea producens 3L C                              ~~~~~~~~~~~~~~~~~~~~MKLPKQTAPIQRKVSGTTLSLNNGVN~~~~~~~~~~~GVEAS~~~~~~~~~~~~~~~DTIDDVLRVTEAVAPIVTPVLTAAIGSLI           
Mycobacterium vulneris B                           ~~~~~~~~~~~~~~~MSTANEMLPPQASPIDRTPAGAAAFTNQA~~~~~~~~~~~~~GVGAS~~~~~~~~~~~~~~~FDFPWEQVATTGIGILGGLL     
 
 
 
Figure 4.1.2.1. Cyanobactin-like precursor peptide alignment. Detected core peptides encoded in larger precursors are highlighted in yellow. 
 
No cysteine 
containing 
core peptides 
Protease  
cleavage site 
 
 
Core peptideLeader peptide 
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Table 4.1.2.2. Overview of the bacterial strains and their predicted core peptides in the study. 
 
Strain 
 
Length 
AA 
(core) 
 
Cysteine 
(core) 
 
Charge 
(core) 
 
Exact 
mass 
 
AA-sequence (core) 
 
Application 
and/or result 
Leptolyngbya 
sp. PCC 7375 A 
61 (26) 
 
4 
 
-2 
 
2769.1 
 
LGWCRNDDDCGAGASCRYGTCVGDYL 
 
 
Leptolyngbya 
sp. PCC 7375 B 
64 (35) 4 -3 3707.5 
 
GSIAASGYFYDCDAHTDCPPGKICDGGICL
NVPWY 
 
Leptolyngbya 
sp. PCC 7375 C 
63 (31) 4 3 3670.76 IKRTHACRNAVYECQTIGHWPACDYVRKH
CL 
Synthetic peptide 
used for 
optimization 
 
Leptolyngbya 
sp. PCC 7375 D 
79 (51) 4 -1 5957.6 ATYEQQQCTWAEYECHESDGTNATACNN
YAAWGCTPNPRFSWNRVRVIRNF 
 
Leptolyngbya 
sp. PCC 7375 E 
73 (45) 4 1 5381.47 RLSRQCALWAEMCHIQDNQEACQLHQEQC
QPRPNSPWGAHWQRRG 
 
Leptolyngbya 
sp. PCC 7375 F 
 
77 (47) 4 -1 5418.45 IRAARQWCCTAEKNGQTINLGCNQPPWYH
ESGLFDSRDYDTVNCYPV 
 
Leptolyngbya 
sp. PCC 7375 G 
 
75 (44) 3 2 5020.42 LFGIRMNLLHGANYNDPAPFDYRRVKQYS
SMCCQRCALDATGIL 
 
Leptolyngbya 
sp. PCC 7375 H 
 
63 (26) 0 0 3044.64 KYHVKFASDDPTTYLLKMALLHLLVE  
Gloeocapsa sp. 
PCC 7428 
82 (53) 10 -1 5873.31 ENLCSCHGVWFQCVINWNRCPQGYHPTCD
GNGFNCFCRCCPDSGQGPCMGPYA 
 
Calothrix sp. 
PCC 6303 A 
56 (29) 6 1 3291.37 GWNRPCNCTIPCRRSREACEDCFAACSPF  
Calothrix sp. 
PCC 6303 A 
60 (32) 6 -1 3380.33 FFCPIGCGGGNFCPEGTFCTNTGFMSCECVP
R 
 
Oscillatoria sp. 
PCC 10802 A 
50 (25) 0 -1 2668.5 AWYDTVLDVVKTVAPIAAPILTSLI  
Oscillatoria sp. 
PCC 10802 B 
52 (24) 0 0 2558.44 AWYDTLLEVAKKVAPIATTVLGSL Antimicrobial 
activity (synthetic) 
 
Oscillatoria sp. 
PCC 10802 C 
50 (25) 2 1 2684.24 GASISDYTSCYNLKGLARNLCMAAY Synthetic peptide 
used for 
optimization 
 
Oscillatoria sp. 
PCC 10802 D 
79 (55) 4 2 5969.75 VKDSKGRLSRREYQYVHGSNPNPNAPMKF
SEPADCGCPIFSGVSMAMCFAACGIF 
 
Oscillatoria sp. 
PCC 10802 E 
79 (49) 3 0 5243.39 GFCFYGAGDDPLAWTRAQAQYGYCPGTN
AKVWVNNIGDGQNACTAGLFR 
 
Microcystis 
aeruginosa PCC 
9443 
72 (44) 6 2 4535.14 NLALACDLCCQSGGGIACGAISGCSCPLWL
FVTLYAKSTNKMPR 
 
Cylindrospermu
m stagnale PCC 
7417 
80 (52) 10 1 5371.27 VFNPCACHAKGLGCIVTRNDCPAGWMPRC
EVQLGAGCVCYCCSATGTCSGPY 
 
Pseudanabaena 
sp. PCC 6802 A 
58 (29) 6 0 2993.35 NWKLRCDLCCEAGGGAVCNSILPGCVCPL  
Pseudanabaena 
sp. PCC 6802 B 
72 (45) 8 -3 4718.01 ECSYLRCGAKVLECASACYEGGVAACLA
CLGPSYEACKDCFSDIF 
Detected 
Pseudanabaena 
sp. PCC 6802 C 
59 (32) 8 -1 3205.28 ASKCCGSDEYCLGSCICFLGDCSCAGAC
VPKL 
Detected 
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Pseudanabaena 
sp. PCC 6802 D 
73 (45) 8 1 4216.85 GCSTWKKIGCAGAVAACAAVCYASGGL
ACAGCFAGLGQSSCIDCL 
Detected 
Mastigocladopsi
s repens PCC 
10914 A 
72 (44) 4 0 4862.31 QVLSTLLPIEGPNFDTCYRTCRFYGGGRVG
CFLSCLSWIGTFAD 
 
Mastigocladopsi
s repens PCC 
10914 A 
82 (54) 8 -1 6087.75 QLSITNEFEEENVRRTIVGYVRNIVSQGCFP
CCFCCNQGNCCAECREKNLAANL 
 
Tolypothrix PCC 
7910 A 
58 (30) 6 1 3169.44 QNFQLQCALCCQNGGLATCNSILPGCVCRL  
Tolypothrix PCC 
7910 B 
54 (30) 2 -2 3140.55 AAIFGINLCDLMPEPERTACHIAGKLAGTE Synthetic peptide 
used for 
optimization 
Streptomyces 
davawensis JCM 
4913 A 
59 (20) 2 2 2063.82 RSMCAGMTGSARDMCRSMGG  
Streptomyces 
davawensis JCM 
4913 B 
62 (23) 0 -3 2393.21 DSNGVEADFDFGGLLKTVANVLL  
Streptomyces 
davawensis JCM 
4913 C 
70 (23) 0 0 2416.3 LGWSDIPWHAIGKAARGALDAVL  
Streptomyces 
davawensis JCM 
4913 D 
66 (22) 0 -2 2206.22 EPNLPILPLLGLAGSAIGSLFD  
Mesorhizobium 
alhagi HAMBI 
3019 A 
58 (31) 8 0 2903.16 DCCGAGRCCVGACLPFGGGCAGICVPNIGQ
C 
 
Mesorhizobium 
alhagi HAMBI 
3019 B 
70 (45) 8 0 4241.84 SGCNVFKAIRCAASVAACVASCAAGPAACI
ACFAGIGASDCMDCL 
 
Aurantimonas 
manganoxydans 
DSM 21871 
69 (43) 8 0 4233.86 GCNVLDWVVCGATVAACAPACVAGPATC
ALCMGAAYDRCKNCL  
 
Dickeya zeae 
Ech1591 
49 (22) 0 2 2272.29 FWGEALKLLKKAGQGALSGVLS Antimicrobial 
activity (synthetic) 
Vibrio 
nigripulchritudo 
SOn1 A 
49 (22) 0 2 2324.24 FWGTAFDILKKAGKGALQGVMS Antimicrobial 
activity (synthetic) 
Vibrio 
nigripulchritudo 
SOn1 B 
49 (22) 0 2 2294.22 FWGGVFDVLKKAGKGALQGVMS Antimicrobial 
activity (synthetic) 
Agarivorans 
albus MKT 106 
49 (22) 0 1 2228.23 FWGGVLDVLKKAGQGALNGVLS Antimicrobial 
activity (synthetic) 
Roseibium sp. 
TrichSKD4 B 
53 (26) 0 3 2678.57 FWGALASAAAPIAIDLGKKALRGLLR Antimicrobial 
activity (synthetic) 
Yersinia 
frederiksenii 
ATCC 33641 
49 (22) 0 1 2215.24 FWDSVLSVLKKAGQGALAGVLG Antimicrobial 
activity (synthetic) 
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4.1.1 Phylogenetic analysis of proteases from candidate strains  
 
The cyanobactin-like protease and the cyanobactin proteases were aligned using MUSCLE 
alignment and GBLOCKS curation. A PhyML phylogenetic tree was constructed in order to 
reconstruct the evolutionary history of cyanobactin genes and establish the relationships 
between cyanobactin and cyanobactin-like gene clusters. The tree shows complex evolutionary 
history and cyanobactin-like proteases show broader diversity than the cyanobactin proteases 
(PatA and PatG) (Figure 4.1.3). Majority of cyanobacteria can be differentiated as their own 
group highlighted in light grey, whereas another subgroup of proteases form a distinctive group 
highlighted in dark grey. Interestingly, cyanobactin proteases highlighted in yellow have 
clustered apart from each other (Figure 4.1.3). 
 
 
Figure 4.1.3. Phylogenetic tree showing the relationship between cyanobactin-like -and 
cyanobactin proteases. Cyanobactin proteases are highlighted in yellow.  
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4.2 Optimization for detection of synthetic peptide standards 
 
Three peptides used for optimization were synthesized based on peptide predictions (Figure 
4.2). These peptides contain 2–4 cysteines in their sequence and disulphide-bridge formation is 
supposed. Optimization for detection with synthetic peptides resulted that the best extraction 
method for bacterial samples is 50 % methanol. Other methods tested were pure methanol, pure 
water and 0.1 % formic acid. With these extraction methods, there were no differences between 
glass or plastic vials used for cyanobactin-like peptide detection. Detection limit was 
determined by dilution series to be 6–100 ng/ml, but more reliable limit was 60–100 ng/ml 
(Figure 4.2.1). 
 
Oscillatoria sp. PCC10802 D     ~~~~~~~~~MNNLPKQSQPVVRNINTTSP~~~~~~~~~~~~~~~~~~LLNSS~~~GASISDYTSCYNLKGLARNLCMAAY                      
Leptolyngbya sp. PCC 7375 C     ~~~~~~MKTKNLRPRLNAPVDRTNVVSIFKGQN~~~~~~~~~~~~~~GVSPS~~~IKRTHACRNAVYECQTIGHWPACDYVRKHCL                
Tolypothrix PCC 7910 B          ~~~~~~~~~~MKLPIQAQPIKRGVSTAHM~~~~~~~~~~~~~~~~~~QNLVN~~~AAIFGINLCDLMPEPERTACHIAGKLAGTE                 
 
Figure 4.2. Synthetic peptides used for optimization highlighted in yellow.  
 
 
Figure 4.2.1. Dilution series of GASIS-peptide diluted in water. 
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4.3 Detection of the peptides from Pseudanabaena sp. PCC 6802 by mass using Q-TOF  
 
 
Crude extract of Pseudanabaena sp. PCC 6802 was analyzed with Q-TOF. The flight times of 
peptide molecules and masses matched with predictions and Pseudanabaena sp. PCC 6802 
produces these peptides (Figures 4.3 a-c). For all the detected peptides the error rate between 
theoretical m/z -values and detected m/z –values was ≤3.5 ppm. Detected masses for EGG-
peptide were 1178.4963 and 1570.9902; for ASK-peptide 800.3132, 1066.7485 and 1599.6189; 
and for CAGA-peptide 1053.2001 and 1403.9377 (Table 4.3 and Figures 4.3 a-c).  
 
 
 
Figure 4.3 a. Q-TOF –profile of EGG-peptide. The two predominant peaks show the mass 
values of quadrapole (1178.4963 m/z) - and triple (1570.9902 m/z) charged forms. 
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Figure 4.3 b.  Q-TOF –profile of ASK-peptide. The predominant peak shows the mass value of 
triple (1066.7485 m/z) charged form. 
 
 
 
 
Figure 4.3 c.  Q-TOF –profile of CAGA-peptide. The second predominant peak shows the mass 
value of quadrapole (1053.2001 m/z) charged form.  
pcc6802 + peptides
m/z
500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
16101423 476 (2.215) AM2 (Ar,20000.0,0.00,0.00); Cm (475:477) 1: TOF MS ES+ 
3.46e51067.4166
1067.0833
1066.7485
800.8127
800.5638
800.3132
758.7697
758.4340569.3300
500.2033 !
718.4051
814.0425
814.2920
814.5419
814.7930
815.0451
815.2924
893.4380 919.4501 !
986.4830
1067.7505
1068.0837
1068.4165
1068.7501
1069.0851
1085.7212
1155.5273 1600.6187
1188.5756
!
1378.7056 1601.6169
pcc6802 + peptides
m/z
500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500 1550 1600 1650 1700 1750 1800 1850 1900 1950
%
0
100
16101423 565 (2.622) AM2 (Ar,20000.0,0.00,0.00); Cm (547:571) 1: TOF MS ES+ 
4.16e5864.8160
864.4808
859.4826
585.2836
!
569.3074
!
514.2017
859.1486
587.2896
855.1476
601.2659 !
739.3984
603.2792
658.3467
662.3412
739.7368 854.1542
851.3863
!
769.3911
848.3823
838.4018
865.1497
1054.4598
1054.2039
1053.9545
1053.4626
865.4822
1046.4974
870.4382
1012.4835
965.4661
1054.7029
1054.9540
!
1540.4541
1055.2053 !
1540.3110
1059.5038 !
1540.1646
1061.4695
1061.7037
1404.6067
1063.4895
1105.5291
1405.6112
!
1540.5977
!
1540.8843
!
1541.0314
!
1797.1956
!
1796.8602
!
1548.0100
!
1796.6902
!
1797.3624
!
1797.5348
!
1797.7041
!
1797.8708
!
1798.0370
44 
 
 
From every peptide their triple- and quadrapole charged forms were detected, and in addition 
double charged form from ASK-peptide (Table 4.3). Cyanobactin-like gene cluster in this strain 
contains four precursors from which three predicted core peptides were detected (Figure 4.3.1). 
 
 
 
Figure 4.3.1. Cyanobactin-like gene cluster from Pseudanabaena sp. PCC 6802 illustrating the 
precursor genes from which predicted core peptides were detected.  
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Table 4.3. Cyanobactin-like precursor genes from Pseudanabaena sp. PCC 6802 
 
Gene 
Amino acid sequence 
 (core peptide) 
Elemental 
composition 
Charge Theoretical m/z Detected m/z 
Error 
(ppm) 
pseE1 NWKLRCDLCCEAGGGAVCNSILPGCVCPL 
(Not detected) 
C125H198N36O37S6 
 
5 598.4687   
   4 747.8339   
   3 996.7759   
   2 1494.66   
   1 2988.3121   
pseE2 ECSYLRCGAKVLECASACYEGGVAACLACLGPSYEACKDCFSDIF 
(Detected) 
C201H300N50O65S8 
 
5 942.9973   
   4 1178.4946 1178.4963 1.4 
   3 1570.9902 1570.9902 0.0 
   2 2355.9814   
   1 4710.9551   
pseE3 
ASKCCGSDEYCLGSCICFLGDCSCAGACVPKL 
(Detected) 
C130H200N34O44S8 
 
5 640.4523   
   4 800.3134 800.3132 -0.2 
   3 1066.7486 1066.7485 -0.1 
   2 1599.619 1599.6189 -0.1 
   1 3198.2302   
pseE4 
GCSTWKKIGCAGAVAACAAVCYASGGLACAGCFAGLGQSSCIDCL 
(Detected) 
C176H273N49O55S8 
 
5 842.7646   
   4 1053.2038 1053.2001 -3.5 
   3 1403.9357 1403.9377 1.4 
   2 2105.3997   
   1 4209.7916   
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4.4 Sulphur labelling 
 
 
The pse gene cluster containing Pseudanabaena sp. PCC 6802 was grown in media including 
normal sulphur 32S- isotope and 34S-isotope in order to find cysteine-rich peptides by LC-MS. 
Sulphur containing EGG-peptide was found by comparing 34S-labeled LC-MS profile to the 
LC-MS profile of the unlabeled one. The aminoacid sequence of the EGG-peptide should 
contain eight cysteine residues. In the presence of 34S, two sulphur-atoms are attached to each 
cysteine. This gives 16 mass unit addition to mass. The compound with bigger mass can be seen 
in the presence of 34S, but not in the presence of 32S (Figure 4.4). 
 
 
 
  
 
Figure 4.4. LC-MS –profile of the quadrapole charged EGG-peptide between PCC 6802 32S 
(1179 m/z) and PCC 6802 34S (1183 m/z). 
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4.5 Heterologous expression of the pse gene cluster in Escherichia coli 
 
In order to support the result of finding predicted peptides by Q-TOF and sulphur labeling, the 
pse gene cluster from Pseudanabaena sp. PCC 6802 was amplified by PCR with specific 
primers, restricted with restriction enzymes, subcloned to two vectors and heterologously 
expressed in E. coli. The pse gene cluster from S. davawensis JCM 4913 was cloned as well. 
The 3485 bp long gene cluster from Pseudanabaena sp. PCC 6802 was successfully cloned and 
expressed in E. coli BL21-cells containing the genes needed for peptide expression. The 
quadrapole charged EGG-peptide in E. coli BL21-cells was detectable at m/z 1179.2 (Figure 
4.5). Both of the vectors, high copy number plasmid Puc57 and low copy number plasmid 
Pacyc84 (data not shown), contained T7-promoter and ribosomal binding site and they both 
worked. Five parallel colonies were selected to the cloning procedure to make sure that at least 
one colony features the pse gene cluster and to compare expression levels between clones. All 
of the parallel colonies included the gene cluster, but in sample No. 2 the expression level of the 
gene product (EGG-peptide) was largest. Expression level in sample No. 2 is about six times 
larger compared with the Pseudanabaena sp. PCC 6802 -ctrl and expression level is about five 
times larger with IPTG-induced sample No. 2 compared with the crude extract Pseudanabaena 
sp. PCC 6802 -ctrl (Figure 4.5). Only EGG-peptide was detected from clone sample, ASK -and 
CAGA-peptides were not detected. The pse gene cluster from S. dawavensis JCM 4913 was not 
detected either. Surprisingly, there was no noteworthy enhancement of expression levels in any 
of the samples treated with IPTG-induction (Figure 4.5).  
 
 
 
Figure 4.5. Heterologous expression of Pseudanabaena sp. PCC 6802 gene cluster in Puc57-
plasmid in E. coli BL21-cells for quadrapole charged EGG-peptide at m/z 1179.2.   
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Clone samples, which expression levels of peptide were largest (2. CTRL and 2. IPTG), and 
Pseudanabaena sp. PCC 6802 crude extract were also analyzed by Q-TOF. Expression levels of 
EGG-peptide are larger in clone samples compared to crude extract sample (Figure 4.5.1). 
 
 
  
Figure 4.5.1. Q-TOF-profile of the quadrapole charged EGG-peptide from Pseudanabaena sp. 
PCC 6802 at m/z 1179.24. Sample A represents IPTG induced clone sample expressed in E. coli 
BL21-cells, sample B represents non-IPTG induced clone sample and sample C is 
Pseudanabaena sp. PCC 6802 crude extract. 
 
 
A 
B 
C 
49 
 
4.6 Antimicrobial assays  
 
Detection of the peptides from Pseudanabaena sp. PCC 6802 prove that protease cleavage site 
of the precursor was predicted right, confirmed by Q-TOF and sulphur labeling. Heterologous 
expression demonstrate that the boundaries of the gene cluster were correctly defined. This 
information mean that it was possible to accurately predict the cleavage site for all precursor 
peptides identified in the bioinformatics analysis. Further examination by bioinformatic analysis 
revealed a smaller group of cyanobactin-like peptides from various bacterial genomes which 
contain no cysteine in their core sequences and they resemble known α-helical antimicrobial 
peptides by their structure (Figure 4.6). Antimicrobial activity of these novel peptides was so 
hypothesized. Some of these peptides were synthesized and tested for their bioactivity. 
 
 
 
     PCC 6802 pseE2                    MKLPIQAQPVMRGVSSSKLAGK~~~~TITPS~~~~~~~~~~ECSYLRCGAKVLECASACYEGGVAACLACLGPSYEACKDCFSDIF 
     PCC 6802 pseE3                    MKLPIQAQPVLRQLNNYTSQHQ~~~~GILPS~~~~~~~~~~ASKCCGSDEYCLGSCICFLGDCSCAGACVPKL 
     PCC 6802 pseE4                    MKLPVQAQPVLRNVSDTKIAMTN~~~AVIAS~~~~~~~~~~GCSTWKKIGCAGAVAACAAVCYASGGLACAGCFAGLGQSSCIDCL  
     Dickeya zeae Ech1591              MKLPTQAQNVNRANRVAEAKAS~~~~GVNPA~~~~~~~~~~~FWGEALKLLKKAGQGALSGVLS 
     Vibrio nigripulchritudo SOn1 A    MKLPTQAPGVDRSNRLEAAQAA~~~~GVNPA~~~~~~~~~~~FWGTAFDILKKAGKGALQGVMS                         
     Vibrio nigripulchritudo SOn1 B    MKLPTQAPGVDRSNRLEAAQAA~~~~GVNPA~~~~~~~~~~~FWGGVFDVLKKAGKGALQGVMS 
     Yersinia frederiksenii ATCC 33641 MKLPIQAQSVNRSNRIAEAKMA~~~~GVNPA~~~~~~~~~~~FWDSVLSVLKKAGQGALAGVLG 
     Agarivorans albus MKT 106         MKMPIQAQSVDRSNRIAEAKAA~~~~GVNPA~~~~~~~~~~~FWGGVLDVLKKAGQGALNGVLS 
     Roseibium sp. TrichSKD4 b         MKLPYQAPSINREDRINSAIDS~~~~SVAPA~~~FWGALASAAAPIAIDLGKKALRGLLR 
Oscillatoria sp. PCC10802 B       MNLPKQVAPVERTLTPAAISGQS~~~GVEAS~~~~~~~~~~AWYDTLLEVAKKVAPIATTVLGSL 
 
      
Figure 4.6. Amino acid sequence alignment between detected cysteine containing peptides from 
Pseudanabaena sp. PCC 6802 (highlighted in grey) and predicted core peptides with 
antimicrobial activity of the same family from different bacterial strains with double lysine-
motif as a connective factor (highlighted in green). Conserved residues in the leader peptide are 
highlighted in yellow.  
 
 
I had 11 synthetic analogs of peptide predictions (Table 3.6) from which seven were discovered 
to have antimicrobial activity (Table 4.7). Peptides from Oscillatoria sp. PCC 10802 (B), 
Dickeya zeae Ech1591 (D) and Vibrio nigripulchritudo SOn B (V) were shown to be active 
against Gram-negative and Gram-positive bacteria in disk diffusion assay (Table 4.6 and figure 
4.6.1 a-f). Synthetic peptide A dissolved poorly in 50 % methanol and manifested no 
antimicrobial activity against tested strains, nor did the synthetic cysteine containing ones 
(GASIS, NAVY, AAIF) (Table 4.6). Pseudomonas sp. and Pseudomonas aeruginosa appeared 
to be resistant to tested peptides. Peptide A has a charge -1, peptide B has neutral charge and 
peptides D and V carry charge +2. The two cationic peptides (D and V) exhibited strong 
antimicrobial activities in contrast to the neutral peptide B and negatively charged peptide A. 
Leader peptide 
Protease 
cleavage 
site Core peptide 
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There was no detectable amendment in antimicrobial activity when peptides A and B were used 
in tandem. For peptides D and V the results were the same so the experiment was reproductive.  
 
 
Table 4.6. Antibacterial activity of peptides against various bacterial strains. Number stands for 
radius of inhibition in mm.  
 
 
Bacteria (HAMBI nr.) Gram Gasis Navy Aaif 
PCC 10802 
A 
PCC  10802 
B 
Dickeya 
(D) 
Vibrio 
(V) 
+ ctrl - ctrl 
Pseudomonas sp.(2796) - - - - - - - - 17 - 
Pseudomonas aeruginosa (25) - - - - - - - - 12 - 
Escherichia coli (396) - - - - - 5 6 6 18 - 
Burkholderia pseudanalbei (33) - - - - - - 5 4 15 - 
Salmonella typhi (1306) - - - - - - 6 6 16 - 
Xanthomonas campestris (104) - - - - - - 4 5 18 - 
Burkholderia capacia (2487) - - - - - - 4 - 17 - 
Bacillus cereus (1881) + - - - - 4 - - 18 - 
Micrococcus luteus (2688) + - - - - 5 6 6 20 - 
Staphylococcus aureus (11) + - - - - - 4 3,5 15 - 
Bacillus subtilis (251) + - - - - - 5 6 19 - 
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(a)                   (b) 
  
(c)                 (d) 
  
(e)                 (f) 
  
Figure 4.6.1. Disk diffusion assay illustrating the bioactivities of synthetic peptides against various 
bacterial strains. A and B are the peptides from Oscillatoria sp. PCC 10802, D is the peptide from 
Dickeya zeae ech1591 and V is the peptide from Vibrio nigripulchritudo SOn1. (a) E. coli (396), (b) 
M. luteus. (2688), (c) S. aureus. (11), (d) B. pseudanalbei (33), (e) B. subtilis. (251), (f) X. 
campestris. (104). Mass of each synthetic peptide/disk was 60 µg, negative control was methanol 
and positive control was kanamycin (1000 µg/disk).  
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4.6.1 Antimicrobial peptide database results 
 
Amino acid sequences of the seven antimicrobial peptides were used to query the database at 
antimicrobial peptide database (Wang et al. 2009). The database search resulted in many hits 
from which the closest are reported in Table 4.6.1. 
 
Table 4.6.1. Antimicrobial peptides in the study used to query known antimicrobial peptides 
from database.  
 
 
Producer strain 
of peptide 
Peptide 
(Similarity percentage) 
Origin Bioactivity Reference 
Dickeya zeae 
ech1591 
Macropin 1 (47.82 %) Bee venom Against B. subtilis, E. coli, S. aureus and C. 
albicans 
 
Monincová et 
al. (2014). 
Vibrio 
nigripulchritudo 
SOn1 A 
Magainin-MW1 (48 %) Frogs, 
amphibians 
and animals 
Against E. coli, S. aureus and C. albicans 
 
Mechkarska et 
al. (2011). 
Vibrio 
nigripulchritudo 
SOn1 B 
Plasticin PD36K (48 %) Synthetic Against S. aureus, B. megaterium, E. coli and 
E. cloacae 
El amri et al. 
(2006). 
Yersinia 
frederiksenii 
ATCC 33641 
Peptide PGQ (50 %) Frogs, 
amphibians 
and animals 
Against E. coli, K. pneumonia, P. aeruginosa, 
S. aureus, S. faecalis and C. albicans 
Moore et al. 
(1991). 
Agarivorans 
albus MKT 106 
Peptide PGQ (51.85 %) Frogs, 
amphibians 
and animals 
Against E. coli, K. pneumonia, P. aeruginosa, 
S. aureus, S. faecalis and C. albicans 
Moore et al. 
(1991). 
Roseibium sp. 
TrichSKD4 B 
Brevinin-1Ja (46 %) Frogs, 
amphibians 
and animals 
Against S. aureus, E. coli and 
mammalian COS7-cells 
 
Koyama and 
Iwamuro 
(2008). 
Oscillatoria sp. 
PCC10802 B 
Dermaseptin-H13 (44.44 %) Frogs, 
amphibians 
and animals 
Against S. aureus, P. aeruginosa, and E. coli Navon-
Venezia et al. 
(2002). 
 
 
4.7 MIC (minimum inhibitory concentration) 
 
All the peptides, which had detected antimicrobial activity in disk diffusion assay, were tested 
for their MIC-values against Gram-positives S. aureus, B. subtilis, M. luteus and Gram-negative 
E. coli. Additionally four more peptides were ordered synthetic and these were from 
Agarivorans albus MKT 106, Roseibium sp. TrichSKD4, Yersinia frederiksenii ATCC 33641 
and another peptide of the same gene cluster from Vibrio nigripulchritudo SOn1. Also the 
peptides from Dickeya zeae Ech1591 and Vibrio nigripulchritudo SOn1 were ordered with 
higher purity (98 %) in comparison with the purity (75 %) that was used in disk diffusion assay. 
Table 4.7 summarizes the MIC- values of the peptides used in this study, which are between 
0.78-100 µg/ml. Peptide A from Oscillatoria sp. PCC 10802 and the synthetic cysteine 
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containing ones (GASIS, NAVY, AAIF) were not included in the test, because they showed no 
activity in disk diffusion assay. There was no detectable amendment in MIC-values when both 
peptides from Vibrio nigripulchritudo SOn1 were used in tandem. All the peptides are cationic 
with a net charge ranging between 1–3, except the peptide from Oscillatoria sp. PCC10802 B 
which had a net charge of 0. MIC-test was done in order to find out the lowest concentration of 
peptide inhibiting the growth of bacteria. 
 
 
Table 4.7. Minimum inhibitory concentrations (MIC) of the synthetic antimicrobial peptides 
 
Strain 
(Antimicrobial 
peptide) 
 
Peptide sequence 
 
MIC    
(µg/ml) 
 
   
  
S. aureus 
 
B. subtilis 
 
E. coli 
 
M. luteus 
 
 Agarivorans albus 
MKT 106 (85.7 %) 
 
FWGGVLDVLKKAGQGALNGVLS 
 
ND ND ND 50–100 
 
Dickeya zeae 
Ech1591 (98.8 %)* 
 
FWGEALKLLKKAGQGALSGVLS 
 
25–50 12.5–25 12.5–25 3.125–6.25 
Roseibium sp. 
TrichSKD4 b 
(87.4%) 
 
FWGALASAAAPIAIDLGKKALRGLLR 6.25–12.5 3.125–6.25 25–50 0.78–1.5625 
Vibrio 
nigripulchritudo 
SOn1 A (98.1 %)* 
 
FWGTAFDILKKAGKGALQGVMS ND 12.5–25 25–50 3.125–6.25 
Vibrio 
nigripulchritudo 
SOn1 B (98.1 %)* 
 
FWGGVFDVLKKAGKGALQGVMS 25–50 6.25–12.5 25–50 
1.5625–
3.125 
Yersinia 
frederiksenii 
ATCC 33641 
(96.4%) 
 
FWDSVLSVLKKAGQGALAGVLG 50–100 25–50 ND 12.5–25 
Vibrio 
nigripulchritudo 
SOn1 A + B* 
 
FWGTAFDILKKAGKGALQGVMS  + 
 FWGGVFDVLKKAGKGALQGVMS 
25–50 6.25–12.5 25–50 
1.5625–
3.125 
Oscillatoria sp. 
PCC 10802 B 
(75%) 
 
AWYDTLLEVAKKVAPIATTVLGSL 
 
ND ND ND 
12.5–25 
 
*= Three peptides were synthesized with ~98 % purity, meaning that the net content of the peptide is 50 
% according to the manufacturer (GenScript). Then the actual MIC-value would be half of the actual 
observed values (reported in the table). ND = not determined.   
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5. DISCUSSION   
 
5.1 Novel antibacterial peptidefamily  
 
Here I report a new group of antimicrobial peptides from bacteria. Cyanobactin-like gene 
clusters encoding peptides have been identified in the genomes of bacteria spanning six phyla.  
 
Cyanobactins have been proven to be widespread among cyanobacteria (Leikoski et al. 2009), 
but the presence of cyanobactin gene clusters outside cyanobacterial phyla has not yet been 
proven. Our study suggests that the putative cyanobactin-like gene clusters are widespread in 
cyanobacteria and proteobacteria. Another as widely distributed group of peptides are microcins 
(Lee et al. 2008). Gene clusters encoding ribosomally produced microcin (produced by Gram-
negative bacteria) homologs have been identified in the genomes of archaea as well as bacteria 
covering also six phyla, including cyanobacteria, actinobacteria, and proteobacteria (Lee et al. 
2008). The widespread occurrence between various bacterial phyla of gene clusters encoding 
antimicrobial peptides suggest that they play valuable roles in microbial biology and physiology 
(Claesen and Bibb 2010).  
 
Disulphide-bridge containing peptides and α-helical peptides are widely distributed in 
multicellular organisms with great diversity (Tossi et al. 2000; Zasloff 2002). Antimicrobial 
peptides with disulphide-bridges from bacteria are not well known, but some peptides with these 
characteristics are published (Duquesne et al. 2007; Singh et al. 2012; O’shea et al. 2013). 
Peptides with α-helical structure are not well known from bacteria either, except cecropins from 
Helicobacter pylori (Pütsep et al. 1999). Previously genome mining has revealed various 
structurally complex peptides with antimicrobial activity from different sources including 
micro-organisms and higher organisms (Challis 2008). These findings indicate that bacteria 
produce eukaryotic-like antimicrobial peptides. 
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5.2 Biosynthesis of cyanobactin-like peptides   
 
The results presented here demonstrate that the gene clusters encoding cyanobactin-like 
peptides contain single protease and 1–8 precursor genes. Cyanobactin gene clusters by contrast 
consist of two proteases and 1–10 precursor genes (Lee et al. 2009; Donia and Scmidt 2010; 
Sivonen et al. 2010; Leikoski et al. 2013). Post-translational modifications for cyanobactin-like 
peptides include proteolytic cleavage and formation of sulphur bridges. In general the 
biosynthetic machinery of cyanobactin-like peptides seems less complex compared to 
cyanobactin machinery, but there could be post-translational enzymes in some of the gene 
clusters that have not been noticed. Genome mining can be targeted to tailoring (modifying) 
enzymes that give core peptide its exotic structure. This extended mining might give insights to 
genes encoding other modifying functions, e.g. methyltransferases, hydroxylases (Baltz 2008), 
export enzymes for external secretion of the peptide (Duquesne et al. 2007) and transferases that 
enact the transfer of some functional groups inside the compound. This would change the 
molecular weight of the peptide and new calculations might be needed for natural product 
detection by chemical analysis. So even if these compounds exist according to predictions and 
are being produced, they would not be detectable with false calculations. The detected 
cyanobactin-like peptides are found inside the cells, which supports the information that the 
cyanobactin-like gene cluster in Pseudanabaena sp. PCC 6802 does not encode an enzyme for 
external secretion of the peptide(s), but this does not necessarily apply to other candidate strains. 
Maybe some portion of these peptides could be found from the extracellular space. Thus it could 
be possible that in some of cyanobactin-like gene clusters there are other post-translational 
enzymes which modify the peptide structure.  
 
The results presented here provide some insights into the evolutionary origins of the 
cyanobactin pathway. Phylogenetic analysis shows that the cyanobactin pathway may have 
emerged through fusion of two cyanobactin-like gene clusters (Figure 4.1.3). Natural product 
variety is driven among others by horizontal gene transfer, gene duplications, gene or partial 
gene deletions, replacements and homologous recombination (Baltz 2008). Horizontal gene 
transfer is likely to happen with cyanobactin-like peptides, because they are widespread 
between bacterial phyla. It is still unclear are the genes needed for cyanobactin-like peptide 
biosynthesis encoded in plasmids or chromosomally. They could be encoded either by plasmids 
or by the chromosome, like microcins, which are produced by enterobacteria and belonging to 
the large class of bacteriocins (Duquesne et al. 2007).  
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The detected cyanobactin-like peptides from Pseudanabaena sp. PCC 6802 are linear by 
structure. Most likely all cyanobactin-like peptides are linear, because they lack the 
macrocyclization motif in the precursor peptide. Another factor supporting linear structure of 
cyanobactin-like peptides is a single protease in the gene cluster. Presence of another protease 
would suggest cyclic structure of the compound, as it is with cyanobactins (Lee et al. 2009; 
Donia and Scmidt 2010; Sivonen et al. 2010).  
 
 
5.3 Detection of new peptides and heterologous expression  
 
Crude extracts from each candidate strain were screened by chemical analysis. Additionally, 
cyanobactin-like gene cluster from Pseudanabaena sp. PCC 6802 was cloned and 
heterologously expressed in E. coli in order to obtain further proof that the cyanobactin-like 
gene cluster was responsible for the production of the disulphide-bridge stabilized peptides 
detected from crude extracts. Three predicted core peptides out of four were detected from 
Pseudanabaena sp. PCC 6802 crude extract by Q-TOF. One of these peptides was detected 
from the E. coli -clone sample expressing the cyanobactin-like gene cluster by LC-MS and Q-
TOF, which proved that the gene cluster is active and the peptide is being produced. The rest of 
the predicted core peptides from remaining candidate strains stayed yet undetected.   
 
Trunkamide, anacyclamides, piricyclamides and patellamide are ribosomal peptides from 
cyanobacteria which all have been successfully cloned and expressed in E. coli (Schmidt et al. 
2005; Donia et al. 2008; Leikoski et al. 2010; Leikoski et al. 2012). The tru gene cluster was 
used to produce peptide variants by introducing mutations into the truE gene and then 
expressing them with the rest of the pathway in E. coli (Tianero et al. 2012). In conclusion, 
there are not that many published expressions in heterologous host of ribosomally produced 
natural products from cyanobacteria (Micallef et al. 2014). Cyanobactin-like peptide (EGG) 
form an adequate addition to this group of cloned secondary metabolite gene clusters based on 
our results.  
 
Many natural product gene clusters remain silent or are not well expressed under standard 
laboratory conditions (Winter et al. 2011). It would be really hard to produce, identify and test 
the bioactivity of gene product if the genes predicted using bioinformatics are inactive 
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(Scheffler et al. 2013). This issue can be resolved by altering the growth conditions of micro-
organism to activate the relevant genes (Scherlach and Hertweck 2006). The growth conditions 
for candidate strains were not altered during this experiment. In order to detect peptides, these 
gene clusters could be cloned and heterologously expressed in E. coli. Heterologous expression 
is a potential method for gene clusters that are silent in their natural host under laboratory 
conditions (Challis 2008). Secondary metabolites lacking in the host organism but present in the 
heterologous host containing the cloned gene cluster could be a proof of active natural product 
production (Zerikly and Challis 2009). Thus, the gene clusters could turn active once cloned and 
the predicted natural product might be produced. On the other hand, gene clusters might be 
active in producer organisms, but the expression levels of the peptides are low and undetectable 
by chemical analysis in that sense. Expression level of detected EGG-peptide is quite large in 
the clone sample so it might overpower the other peptides by its relatively high expression level. 
Biological explanations for nondetection can be among others that the peptides are transported 
out of the cell, they do not exist and/or protease does not cleave every precursor. Consequently, 
gene clusters encoding cyanobactin-like peptides are maybe inactive in most of the candidate 
strains.  
 
S. davawensis JCM 4913 was chosen to be cloned as well in order to prove peptide expression 
from another bacterial strain. However, the predicted peptides were not detected from this 
bacterium. Usually heterologous expression is a powerful method for exploring bacterial 
secondary metabolites, but inadequacies in background metabolism and different codon usage 
might alter pathways from the original organism incompatible with the heterologous host 
(Clardy et al. 2006). S. davawensis JCM 4913 has high GC-content in its genomic DNA. This 
affects codon usage in cloning which might have resulted in poor detection by chemical 
analysis. The cyanobactin-like gene cluster from S. davawensis JCM 4913 includes one V8-like 
protein Glu-specific endopeptidase-like protein. It is not known does this gene have some 
specific role in the protein expression. New heterologous hosts could expand the screening 
efforts to access novel natural products (Clardy et al. 2006).  
 
 
 
 
58 
 
5.4 Antimicrobial characteristics of cyanobactin-like peptides 
 
Some peptides from smaller group of cysteine-free cyanobactin-like peptides originating from 
different bacterial strains were synthesized and tested for their bioactivity. Cyanobactin-like 
peptides without cysteines in their core sequence resemble known α-helical amphiphilic 
antimicrobial peptides by their structure, so antimicrobial activity for this smaller group of 
cyanobactin-like peptides was supposed. This hypothesis was proven by seven synthetic 
peptides manufactured according to predictions. Amphiphilic properties can be seen by the 
alternating order of hydrophobic and hydrophilic amino acids in the core sequence (Tossi et al. 
2000). When the compound is laterally displayed, the negatively charged ends are on the other 
side and the positively charged ends on the opposite side, suggesting that the peptide is able to 
adapt α-helical form at the moment of interaction with bacterial membranes (Tossi et al. 2000; 
Brogden 2005). Currently, the mode of action of cationic hydrophobic antimicrobial peptides is 
assumed as follows: 1) cationic peptides are electrostatically attracted to negatively charged 
microbial surfaces; 2) antimicrobial peptides interact with the negatively charged phospholipid 
head groups of the microbial cytoplasmic membrane; and 3) an amphipathic helical 
conformation may be adapted, which allows peptides to insert the hydrophobic face into the 
bilayer (Tossi et al. 2000). The seven antimicrobial peptides discovered in this study may act on 
microorganisms in a similar manner.  
 
MIC-values for each peptide are within publishable range, albeit we did not use clinically 
important pathogenic strains in antibacterial testing. Cationic antimicrobial peptides have 
showed MIC-values as low as 0.25–4 µg/ml (Moore et al. 1991; Hancock and Lehrer 1998) by 
contrast to our MIC-values which were between 0.78–100 µg/ml. With high probability the 
MIC-values in this study are however underestimated. According to the manufacturer Genscript, 
the net content of the peptide is usually 50–80 %. This means that 50–80 % out of reported 
percentage (75 %–98.8 % in this study) is actually pure peptide. Other substances in the dry 
peptide powder are for example water, absorbed solvents, counter ions and salts. MIC-values 
are likely lower against tested strains.  
 
Antimicrobial peptide magainin 2 is 23 amino acids long and it has a double lysine-motif in the 
residues 10 and 11 (Zasloff 1987). Magainin 2 induces E. coli cell death by permeabilizing the 
cell membrane and causes the efflux of intracellular K+ (Matsuzaki et al. 1997). Synthetic 
antimicrobial peptides from Dickeya zeae Ech1591, Vibrio nigripulchritudo SOn1 (A and B), 
59 
 
Yersinia frederiksenii ATCC 33641, Agarivorans albus MKT 106 are all 22 amino acids long 
and they have double lysine-motif in the same place as magainin 2. When these connective 
factors are taken into account, it can be hypothesized, that these antimicrobial cyanobactin-like 
peptides have a similar mode of action as magainins.  
 
The majority of cyanobactin-like peptides contain cysteine residues in their core sequences, so 
disulphide bridge formations between cysteines is expected as post-translational modifications. 
Post-translational modications involving cysteine residues happen especially frequently in 
RiPPs (Arnison et al. 2013). The antimicrobial activity for these peptides stays yet hypothetical 
and unrevealed. Bactofencin A is a cationic disulphide bridge containing bacteriocin produced 
by Lactobacillus salivarius DPC6502, is active against S. aureus and Listeria innocua. It is an 
unusual bacteriocin resembling eukaryotic defensins, containing two cysteine residues that form 
an intramolecular disulfide bond (O’Shea et al. 2013; O’Connor et al. 2015). This suggests that 
disulphide-bridge containing cyanobactin-like peptides might have antimicrobial activity against 
clinical pathogens. Singh et al. (2012) reported a broadspectrum antimicrobial peptide, 
laterosporulin. It was shown to be resistant to proteolytic enzymes, thermo stable and pH 
tolerant (Singh et al. 2012). Later laterosporulin was proven to inhibit the growth of both Gram-
positive and Gram-negative bacteria (Singh et al. 2015). It is cysteine-rich 49 amino acids long 
peptide produced by Brevibacillus sp. strain GI-9 (Singh et al. 2012). According to Singh et al. 
(2015) laterosporulin adopts a four-strand tangled β-sheet structure stabilized by three 
disulphide-bridges. The intramolecular disulphide-bridges partly determine the intense stability 
for such a short peptide (Singh et al. 2015). The detected EGG-peptide from Pseudanabaena sp. 
PCC 6802 is 45 amino acids long and contains eight cysteines, supposedly forming four 
intramolecular disulphide-bridges. Considering the short length and disulphide-bridges, it can be 
hypothesized that the structure of EGG-peptide is even more rigid and more resistant to 
chemical forces compared to laterosporulin. Additionally, it might have inhibiting effect to the 
growth of Gram-positive and Gram-negative bacteria. 
 
5.5 Classification of cyanobactin-like peptides 
 
Cyanobactin-like peptides can be classified into two different classes according to our findings: 
1) majority with 2–5 disulphide bonds and 2) minority without disulphide bonds. In this sense, 
the classification can be in outline supposed similarly with conus peptides, from which two 
major classes are determined: 1) majority with multiple disulphide bonds, indicated as 
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conotoxins and 2) minority with a single or no disulphide bond (Wang and Chi 2004; Kaas et al. 
2010; Akondi et al. 2014), indicated as conopeptides (Terlau and Olivera 2004). Cyanobactin-
like peptides have much more similarities to the antimicrobial peptides produced by eukaryotes. 
However, conus peptides are of eukaryotic origin and cyanobactin-like peptides arise from 
bacteria, so the appropriate classification scheme for the novel peptides detected here remains 
unclear.  
 
Bacteriocins are ribosomally produced antimicrobial peptides from bacteria (Cotter et al. 2005, 
2013) and they are found in all major lineages of bacteria (Riley and Wertz 2002). Bacteriocins 
are miscellaneous group and they can usually be classified into two classes: 1) Peptides that go 
through post-translational modifications; 2) Unmodified peptides (Cotter et al. 2013). The 
cysteine-rich cyanobactin-like peptides go through some post-translational modifications, which 
are proteolytic cleavage and formation of disulphide-bridges. The cysteine-poor, α-helical 
cyanobactin-like peptides, are proteolytically cleaved according to our bioinformatic results. 
Bacteriocins can be recognized by a double-glycine (GG) motif in the leader peptide sequence 
(Oman and van der Donk 2010; Micallef et al. 2014). From cyanobactin-like peptides, only 
predicted precursors from strains Gloeocapsa sp. PCC 7428 and Aurantimonas coralicida 
DSM-14790 contain this motif in the leader peptide. In this regard, cyanobactin-like peptides 
can not be classified as bacteriocins. However, more data should be obtained regarding the post-
translational modifications in order to enlighten the possible classification together with 
bacteriocins.  
 
Cyanobactins share some characteristics with compounds in bacteriocin superfamily, but they 
can be clearly differentiated as a subgroup based on chemical structures and biosynthetic 
pathway genes (Donia and Schmidt 2010). For cyanobactin-like peptides the classification can 
be similarly thought as with cyanobactins, because they are structurally and biosynthetically 
related to each other. Cyanobactin-like peptides from cyanobacteria have a conserved motif 
(LPxQxxPVxR) in their leader sequence, which is a connective factor with cyanobactins (Oman 
and van der Donk 2010; Leikoski et al. 2013). However, it appears to be more challenging to 
characterize subgroups inside a family that is as multiform as the cyanobactin-like peptides, 
which is also the challence with microcins (Duquesne et al. 2007).  
 
Wang et al. (2011) showed that genes for the biosynthesis of bacteriocins are widespread in 
cyanobacteria. A total of 145 putative bacteriocin gene clusters were recognized in the genomes 
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of 43 cyanobacteria, from which a total of 290 precursor proteins were mapped with size 
varying between 28 to 164 amino acids (Wang et al. 2011). Cyanobactin-like peptides from 
Pseudanabaena sp. PCC 6802 could represent a novel class of bacteriocins from cyanobacteria, 
as the genetic machinery for bacteriocin production is widespread in cyanobacteria. Database 
searches (Wang et al. 2009) for detected cyanobactin-like peptides (EGG, ASK and CAGA) 
have revealed that these peptides do not share prominent homology with previously 
characterized bacteriocins but more closely resemble eukaryotic antimicrobial peptides. It 
would thus appear that cyanobactin-like peptides together with bactofencin A (O’Shea et al. 
2013) are the first novel group of bacteriocins, if classified together with bacteriocins.  
 
5.6 Ecological role, significance and future research of cyanobactin-like peptides 
 
Natural products from microorganisms influence the performance and survival of other 
organisms (Demain and Sanchez 2009). It is suggested that bacteria produce secondary 
metabolites to match against competing microorganisms in their natural environment (Baltz 
2008). Cyanobactin-like peptides might give competitive advantage to its host in an 
environment where there are other bacterial populations in the fight for ecological niches. These 
peptides might represent bacterial analogs for the ones that are present in vertebrates. 
 
Sequences of these peptides are novel which raises the impact of these findings. Cysteine-rich 
cyanobactin-like peptides appear to represent a small class of peptides produced by bacteria, 
together with laterosporulin and bactofencin A (Singh et al. 2012; O’shea et al. 2013). Linear 
peptides are generally poor drug candidates because of their fast degradation and insufficient 
distribution (Velásquez and van der Donk 2011). Albeit, linear peptides with free termini are 
exposed to proteolytic digestion and ribosomal peptides have many ways to occlude the ends of 
the peptide (Leikoski et al. 2013). Thus, the cysteine-free α-helical cyanobactin-like peptides, 
which have antimicrobial activity, might pave the way for new possible drugs derived from 
natural products.  
 
The novel pathway reported in this study probably presents only one fraction of micro-
organisms true metabolic potential. Whole genome sequencing projects have shown that the 
natural product productivity potential of a microorganism is seriously underestimated (Winter et 
al. 2011) and only fraction of these are known products. Structure prediction, structure 
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determination and compound isolation for bioactivity testing could be done for the detected 
peptides. Compound isolation could be done from the heterologous host carrying the 
cyanobactin-like gene cluster from Pseudanabaena sp. PCC 6802, because the peptide 
expression was more extensive compared to crude sample. More work could be done with 
candidate strains in order to detect more natural products corresponding predictions from this 
novel peptide family, for instance cloning of the gene clusters. Bioinformatics could be 
extended aiming to identify all the genes in the gene clusters and to determine the borders of the 
gene clusters, and examine what genes are common to the clusters in addition to the protease 
and precursor genes. These could possibly be additional post-translational enzymes. It can be 
without a doubt presumed that cyanobacteria are and will become more valuable research 
targets of ribosomally produced and post-translationally modified peptides (Velasquez and van 
der Donk 2011; Wang et al. 2011).  
6. CONCLUSIONS    
 
Cyanobactin-like biosynthetic gene clusters were discovered from a wide selection of bacteria 
distributed across the bacterial domain. This novel gene cluster is present in the genomes of 38 
bacteria representing six different phyla. From these we had 12 candidate strains in the study, 
nine cyanobacteria, two proteobacteria and one actinobacteria. Novel disulphide-bridge 
stabilized linear peptides were detected from Pseudanabaena sp. PCC 6802, and the gene 
cluster was successfully expressed in a heterologous host.  After the detection of cysteine-rich 
peptides from cyanobacterium Pseudanabaena sp. PCC 6802 corresponding to bioinformatics 
predictions, more accurate predictions could be done in relation to protease cleavage sites. This 
led to the discovery of peptides with an α-helical structure. These peptides had antimicrobial 
activity between 0.78–100 µg/ml and they have the same ribosomal pathway as the ones in 
Pseudanabaena sp. PCC 6802, excluding formation of disulphide-bridges as post-translational 
modifications.   
 
This study has led to the identification of a new type of antimicrobial peptide produced through 
the proteolytic cleavage of short precursor proteins and provided insights into the origin of the 
cyanobactin biosynthetic pathway. Novel cysteine containing peptides were discovered from 
cyanobacteria with yet hypothetical antimicrobial activity. Interestingly, cysteine-rich- and α-
helical antimicrobial peptides are traditionally believed to be produced only by eukaryotes. This 
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study shows an extensive expansion of natural products produced by bacteria and that their true 
metabolic potential is most likely much wider than anticipated. Genome mining revealed novel 
pathways of antimicrobial peptides from unexplored sources. They are ribosomally produced, 
post-translationally modified, linear and they have antimicrobial activity.  
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